University of Central Florida

STARS
UCF Patents

Technology Transfer

8-14-2012

Methods and compounds for inhibition of cell death
Antonis Zervos

Find similar works at: https://stars.library.ucf.edu/patents
University of Central Florida Libraries http://library.ucf.edu
This Patent is brought to you for free and open access by the Technology Transfer at STARS. It has been accepted for
inclusion in UCF Patents by an authorized administrator of STARS. For more information, please contact
STARS@ucf.edu.

Recommended Citation
Zervos, Antonis, "Methods and compounds for inhibition of cell death" (2012). UCF Patents. 753.
https://stars.library.ucf.edu/patents/753

Illlll llllllll Ill lllll lllll lllll lllll lllll 111111111111111111111111111111111
US008242122B2

c12)

United States Patent

(10)

Zervos

(45)

(54)

METHOD AND COMPOUNDS FOR
INHIBITION OF CELL DEATH

(75)

Inventor:

(73)

Assignee: University of Central Florida Research
Foundation, Inc., Orlando, FL (US)

( *)

Notice:

(21)

Appl. No.: 121751,036

(22)

Filed:

Antonis S. Zervos, Oviedo, FL (US)

Subject to any disclaimer, the term ofthis
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

Mar. 31, 2010

(65)

Prior Publication Data

US 2010/0311772 Al

Dec. 9,2010

Related U.S. Application Data

(63)

Continuation of application No. 10/728,056, filed on
Dec. 4, 2003, now Pat. No. 7,713,981, which is a
continuation-in-part of application No. 10/369,311,
filed on Feb. 20, 2003, now Pat. No. 7,288,546.

(60)

Provisional application No. 60/361,902, filed on Feb.
28, 2002.

(51)

Int. Cl.
AOlN 43154
(2006.01)
C07D 239142
(2006.01)
C07D 401104
(2006.01)
C07D 239100
(2006.01)
C07D 239170
(2006.01)
C07D 471100
(2006.01)
C07D 239102
(2006.01)
U.S. Cl. ......... 514/256; 544/245; 544/299; 544/304
Field of Classification Search .................. 514/256;
544/245, 299, 304
See application file for complete search history.

(52)
(58)

(56)

References Cited

U.S. PATENT DOCUMENTS
6,004,794
6,245,773
2002/0010186
2003/0073629

A
Bl
Al
Al

12/1999
612001
1/2002
4/2003

Karran et al.
Wong et al.
Wong et al.
Alnenni

Patent No.:
Date of Patent:

US 8,242,122 B2
Aug. 14, 2012

OTHER PUBLICATIONS
M. Daemen et al. "Inhibition of apoptosis induced by ischemiareperfusion prevents inflammation," The Journal of Clinical Investigation, vol. 104, No. 5, pp. 541-549, Sep. 1999.
B. Van Der Water et al. "Cleavage of the actin-capping protein ?-adducin at asp-asp-ser-asp 633-ala by caspase-3 is preceded by its
phosphorylation on serine 726 in cisplatin-induced apoptosis ofrenal
epithelial cells," The Journal of Biological Chemistry, vol. 275, No.
33, pp. 25805-25813, Aug. 18, 2000.
G. Kaushal et al. "Role and regulation of activation of caspases in
cisplatin-induced injury to renal tubular epithelial cells," Kidney
International, vol. 60, pp. 1726-1736, 2001.
M. Daemen et al. "Activated caspase-1 is not a central mediator of
inflammation in the course of ischemia-repurfusion," Transplantation, vol. 71, No. 6, pp. 778-784, Mar. 27, 2001.
L. Faccio et al. "Characterization of a novel human serine protease
that has extensive homology to a bacterial heat shock endoprotease
HtrA and is regulated by kidney ischemia," The Journal of Biological
Chemistry, vol. 275, No. 4, pp. 2581-2588, Jan. 28, 2000.
J. Jones et al., "Loss ofOmi Mitochondrial Protease activity causes
the neuromascular disorder ofnmd2 mutant mice," Nature, vol. 425
(6959), pp. 721-727, Oct. 2003.
L. Cilenti et al. "Characterization of a novel and specific inhibitor for
the pro-apoptotic protease Omi/HtrA2," The Journal of Biological
Chemistry, vol. 278, No. 13, pp. 11489-11494, Mar. 28, 2003.
R. Hegde et al. "Identification of Omi/HtrA2 as a mitochondrial
apoptotic serine protease that disrupts inhibitor of apoptosis proteincaspase interaction," The Journal of Biological Chemistry, vol. 77,
No. 1, pp. 432-438, Jan. 4, 2002.

Primary Examiner - Sreeni Padmanabhan
Assistant Examiner - Kendra D Carter

(74) Attorney, Agent, or Firm - Ballard Spahr LLP
(57)

ABSTRACT

The invention is directed to methods and compositions for
inhibiting caspase-independent apoptosis. In particular,
methods and compositions for inhibiting Omi/HtrA2 activity,
as well as method for identifying other inhibitors of Omi/
HtrA2. Also disclosed are Omi/HtrA2 specific substrates and
methods for identifying other substrates ofOmi/HtrA2.
34 Claims, 15 Drawing Sheets
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METHOD AND COMPOUNDS FOR
INHIBITION OF CELL DEATH

prises the tetra peptide motif"AVPS" at its N terminus. It has
been demonstrated that the deregulated expression of Omi/
HtrA2 in the cytoplasm of mammalian cells induces apoptosis in these cells, indicating that Omi/HtrA2 could participate
in the mitochondrial apoptotic pathway.
Mature Omi/HtrA2 is released from the mitochondria into
the cytosol upon disruption of the outer mitochondrial membrane during apoptosis. Mature Omi/HtrA2 can induce apoptosis in human cells in a caspase-independent manner
through its protease activity and in a caspase-dependent manner via its ability to disrupt caspase-IAP interaction.
Since Omi/HtrA2 is present in all mammalian cells and by
its activity of disrupting the inhibition of the "apoptosis protein-caspase interaction" decreases the cell lifetime, it would
be important to discover an inhibitor of the adverse activity of
Omi/HtrA2 and homologous proteins.
Accordingly, it would be useful to identify a class ofinhibitors that inhibit Omi/HtrA2. A need also exists to determine
the peptides involved in the caspase-independent pathway of
apoptosis such as substrates ofOmi/HtrA2, as well as methods and compositions that inhibit such pathways. It would
also be useful to find ways to use these methods and compositions to prevent, reduce or ameliorate a disorder associated
with apoptosis.

RELATED CASE INFORMATION
This is Continuation-In-Part application that claims priority to U.S. Provisional Patent Application No. 60/361,902,
filed Feb. 28, 2002, and U.S. Utility patent application Ser.
No. 10/369,311, filed Feb. 20, 2003, which are incorporated
herein by their entirety.
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BACKGROUND OF THE INVENTION
The technical field of this invention relates generally to
alteration of apoptosis in a cell and modification of pathways
involved in apoptosis including the treatment of diseases that
involve apoptotic pathways. In particular, the invention pertains to a class of inhibitors that inhibit mitochondrial homeostasis, caspase-dependent, and caspase-independent apoptosis by affecting Omi/HtrA2 activity.
Apoptosis, which is also referred to as programmed cell
death, is a form of cell death characterized by membrane
blebbing and nuclear DNA fragmentation. Apoptotic cell
death is morphologically distinct from necrotic cell death and
is important in the normal development and maintenance of
multicellular organisms.
Since apoptosis functions in maintaining tissue homeostasis in a range of physiological processes such as embryonic
development, immune cell regulation and normal cellular
turnover, the dysfunction or loss of regulated apoptosis can
lead to a variety of pathological disease states. For example,
the loss of apoptosis can lead to the pathological accumulation of self-reactive lymphocytes that occurs with many
autoimmune diseases. Inappropriate loss or inhibition of apoptosis can also lead to the accumulation of virally infected
cells and of hyperproliferative cells such as neoplastic or
tumor cells. Similarly, the inappropriate activation of apoptosis can also contribute to a variety of pathological disease
states including, for example, acquired immunodeficiency
syndrome (AIDS), neurodegenerative diseases and ischemic
injury. Treatments that are specifically designed to modulate
the apoptotic pathways in these and other pathological conditions can alter the natural progression of many of these
diseases.
Although apoptosis is mediated by diverse signals and
complex interactions of cellular gene products, the results of
these interactions ultimately feed into a cell death pathway
that is evolutionarily conserved between humans and invertebrates. The pathway, itself, is a cascade of proteolytic events
analogous to that of the blood coagulation cascade.
Several gene families and products that modulate the apoptotic process have now been identified. Key to the apoptotic
program is a family of cysteine proteases termed caspases.
The human caspase family includes Ced-3, human ICE (interleukin-I-beta converting enzyme) (caspase-1), ICH-1
(caspase-2), CPP32 (caspase-3), ICEreZII(caspase-4), ICEreZII
(caspase-5), Mch2 (caspase-6), ICE-LAP3 (caspase-7),
Mch5 (caspase-8), ICE-LAP6 (caspase-9), Mch4 (caspase10), caspase 11-14, and others. Capsases can be positioned as
downstream effectors of apoptosis.
The serine protease Omi, is also involved in apoptosis. Omi
(also known as "HtrA2" and "Omi/HtrA2") was identified as
a mitochondrial direct inhibitor of apoptosis protein (IAP)
binding protein, and is released from the mitochondria upon
induction of apoptosis by apoptotic stimuli (Hegde et al.
(2002) J. Biol. Chem., 277: 432-438). The mature Omi/HtrA2
protein contains a conserved !AP-binding motif that com-
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The invention is based on the discovery that the activity of
Omi/HtrA2 can be inhibited by a class of compounds referred
to as "apoptosis inhibiting compounds." The mature serine
protease Omi/HtrA2 was identified as a mitochondrial direct
baculoviral inhibitor of apoptosis protein repeat3(BIR3)binding protein and a caspase activator (Hegde et al. (2002) J.
Biol. Chem., 277: 432-438). The involvement of a mitochondrial serine protease in the apoptotic pathway emphasizes the
role of the mitochondria in cell death. Therefore, the identification and use of apoptosis. These apoptotic inhibiting compounds can be formulated into pharmaceutical compositions.
The methods and compositions of the invention can be used to
inhibit mitochondrial homeostasis, caspase-dependent, and
caspase-independent apoptosis by affecting Omi/HtrA2
activity.
Accordingly, in one aspect the invention pertains to a pharmaceutical composition for inhibiting cellular apoptosis, the
composition comprising at least one apoptosis inhibiting
compound that can modulate caspase-independent apoptosis.
The pharmaceutical composition can further comprise a
pharmaceutical acceptable excipient. In one embodiment, the
apoptosis inhibiting compound, comprise the general structure shown in FIG. la, where R 1 is selected from the group
consisting of a nitro group, a carboxy group, a hydroxide, an
aliphatic group, an aromatic group, an acyl group, an alkoxy
group, an alkylene group, an alkenylene group, an alkynylene
group, a hydroxycarbonylalkyl group, an anhydride, an
amide, an amine, and a heterocyclic aromatic group. In a
preferred embodiment, the apoptosis inhibiting compound
has the structure shown in FIG. lb. In another embodiment,
the apoptosis inhibiting compound comprises the general
structure shown in FIG. 2a where R 1 is selected from the
group consisting of a nitro group, a carboxy group, a hydroxide, an aliphatic group, an aromatic group, an acyl group, an
alkoxy group, an alkylene group, an alkenylene group, an
alkynylene group, a hydroxycarbonylalkyl group, an anhydride, an amide, an amine, and a heterocyclic aromatic group.
In a preferred embodiment, the apoptosis inhibiting compound has the structure shown in FIG. 2b. In yet another
embodiment, the apoptosis inhibiting compound comprises
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the general structure shown in FIG. 3a, where R 1 is selected
from the group consisting of a nitro group, a carboxy group,
a hydroxide, an aliphatic group, an aromatic group, an acyl
group, an alkoxy group, an alkylene group, an alkenylene
group, an alkynylene group, a hydroxycarbonylalkyl group,
an anhydride, an amide, an amine, and a heterocyclic aromatic group. In a preferred embodiment, the apoptosis inhibiting compound has the structure shown in FIG. 3b. In yet
another embodiment, the apoptosis inhibiting compound
comprises the general structure shown in FIG. 4a, where R 1 is
selected from the group consisting of a nitro group, a carboxy
group, a hydroxide, an aliphatic group, an aromatic group, an
acyl group, an alkoxy group, an alkylene group, an alkenylene
group, an alkynylene group, a hydroxycarbonylalkyl group,
an anhydride, an amide, an amine, and a heterocyclic aromatic group. In a preferred embodiment, the apoptosis inhibiting compound has the structure shown in FIG. 4b.
The pharmaceutical composition may also comprise a mixture of apoptosis inhibiting compounds as long as the apoptosis inhibiting compounds in the mixture can modulate
caspase-independent apoptosis. For example, the composition may have any combinations of the compounds shown in
FIGS. 1-4.
In another aspect, the invention pertains to a method for
inhibiting caspase-independent apoptosis in a cell by contacting a cell having Omi/HtrA2 activity with at least one apoptosis inhibiting compound, such that the apoptosis inhibiting
compound interacts with Omi/HtrA2 to inhibit the activity of
Omi/HtrA2, wherein the inhibition of Omi/HtrA2 activity
reduces apoptosis in the cell; and monitoring the inhibition of
apoptosis.
The inhibiting compound can selected from the group consisting of the structure shown in FIG. la, FIG. 2a, FIG. 3a and
FIG. 4a. Preferably, the apoptosis inhibiting compound has
the structure shown in FIG. lb, FIG. 2b, FIG. 3b, and FIG. 4b.
In yet another aspect, the invention pertains to a method of
inhibiting Omi/HtrA2 activity, comprising contacting a cell
having Omi/HtrA2 activity with an apoptosis inhibiting compound; and monitoring the inhibition of Omi/HtrA2 activity.
The cell to be contacted can either be an in vitro cell or an in
vivo cell. The apoptosis inhibiting compound can be anyone
of the aforementioned inhibitors. The step of monitoring
Omi/HtrA2 activity can be by monitoring a change in fluorescene of an Omi/HtrA2 substrate coupled to a fluorescent
marker, or by monitoring the inhibition of Omi/HtrA2 activity further comprises monitoring apoptosis of the cell.
In yet another aspect, the invention pertains to a method for
modifying a disorder associated with caspase-independent
apoptosis comprising administering a therapeutically effective amount of a composition comprising at least one apoptosis inhibiting compound such that the apoptosis inhibiting
compound interacts with Omi/HtrA2 to inhibit the activity of
Omi/HtrA2, wherein the inhibition of Omi/HtrA2 activity
reduces apoptosis in the cell; and monitoring the amelioration
of the disorder by measuring the change in caspase-independent apoptosis. The disorder can be selected from the group
consisting of kidney failure, heart failure, heart attack, stroke,
neurodegenerative disease, cancers and tumors. In a preferred
embodiment, the disorder is kidney failure.
In yet another aspect, the invention pertains to a method of
preventing tubular cell death, comprising administering an
apoptosis inhibiting compound, wherein the apoptosis inhibiting compound interacts with Omi/HtrA2 such that the apoptosis inhibiting compound interacts with Omi/HtrA2 to
inhibit the activity of Omi/HtrA2, wherein the inhibition of
Omi/HtrA2 activity prevents tubular cell death; and monitoring the prevention of tubular cell death. The tubular cell death

can be associated with the proximal tubules of the kidney, and
may cause renal apoptosis and/or renal ischeamia.
In yet another aspect, the invention pertains to a method for
identifying a substrate associated with caspase-independent
apoptosis, comprising contacting a cell extract with recombinant Omi/HtrA2, wherein the recombinant Omi/HtrA2 has
proteolytic activity. The results from the contacted cell extract
can be compared with the results of the with a control sample
that has not been incubated with recombinant Omi/HtrA2. A
substrate associated with caspase-independent apoptosis can
be identified by monitoring a change in the electophoretic
mobility of a protein in the cell extract incubated with recombinant Omi/HtrA2, such that a change in electophoretic
mobility of the protein indicates that the protein is a substrate
ofOmi/HtrA2. The change in electophoretic mobility can be
the disappearance of a protein in the cell extract incubated
with recombinant Omi/HtrA2. In one embodiment, the protein associated with caspase-independent apoptosis is
obtained from a kidney cell extract. Preferably, the protein
associated with caspase-independent apoptosis is a substrate
for Omi/HtrA2. In one embodiment, the substrate associated
with caspase-independent apoptosis is 14-3-3. In another
embodiment, the substrate associated with caspase-independent apoptosis is Annexin V.
In yet another embodiment, the invention pertains to a
method for identifying a compound that inhibits caspaseindependent apoptosis, comprising contacting the candidate
compound with a substrate coupled to a fluorescent marker in
the presence of recombinant Omi/HtrA2, wherein the recombinant Omi/HtrA2 has proteolytic activity against the substrate, and monitoring the change in fluorescence, whereby a
candidate compound is identified as being an inhibitor of
caspase-independent apoptosis if the candidate compound
inhibits or blocks the proteolytic activity of recombinant
Omi/HtrA2. The substrate can be a specific Omi/HtrA2 substrate selected from the group consisting of 14-3-3 and
annexin V. Alternatively, the substrate can be a general substrate such as casein. The fluorescent marker can be selected
from the group consisting of fluorescein isothiocyanate
(FITC), cyanine dye-5 (CY5), cyanine dye-3 (Cy3), cyanine
dye-7 (Cy7), allophycocyanin (APC), tetramethyl rhodamine
isothiocyanate (TRITC), and phycoerythrin (PE). Preferably,
the fluorescent marker is FITC. The recombinant Omi/HtrA2
is MBP-Omi 134 _458
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FIG. la is the general structure of an apoptosis inhibiting
compound, and FIG. lb is the specific structure ofUcf 101;
FIG. 2a is the general structure of an apoptosis inhibiting
compound, and FIG. 2b is the specific structure ofUcf 102;
FIG. 3a is the general structure of an apoptosis inhibiting
compound, and FIG. 3b is the specific structure ofUcf 103;
FIG. 4a is the general structure of an apoptosis inhibiting
compound, and FIG. 4b is the specific structure ofUcf 104;
FIG. 5 is a schematic drawing showing caspase-dependent
and caspase-independent pathways involving Omi/HtrA2;
FIG. 6 is a schematic drawing showing the functional
domains ofOmi/HtrA2;
FIG. 7 is a graph showing the inhibition of MBP-Omi
(134-458) in the presence of ucf-101 and several other ucf
analogs(•, ucf-101; +, ucf-102; e, ucf-103, .._, ucf-104);
FIG. 8 is a photograph of an SDS-PAGE gel showing the in
vitro proteolytic activity ofMBP-Omi (134-458) in the presence of different concentrations of ucf 101;

US 8,242,122 B2
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FIG. 9 is a graph showing the inhibition of proteolytic
activity ofMBP-Omi (134-458) and MBP-L56 (14-480) ( +,
MBP-Omi; •, MBP-L56);
FIG. 10 is a bar graph showing the inhibition of Omiinduced caspase independent cell death by ucf-101 ;
FIG. lla is a photograph of Western blot showing that the
protein levels of Omi/HtrA2 increases in MPT cells induced
with various cisplatin and antimycin apoptotic stimuli, while
FIG. llb shows the increase in the presence of hydrogen
peroxide;
FIG. 12 is a bar graph showing that ucf-101 blocks cisplatin-induced apoptosis in MPT cells;
FIG. 13 is a schematic drawing showing the different Omi
constructs;
FIG. 14 is a photograph of an SDS-PAGE gel showing the
expression and processing of the various Omi constructs; and
FIG. 15 is a bar graph showing the results of an apoptosis
assay using the various Omi constructs;

"TY"), Caspase-6 (also known as "Mch2"), Caspase-7 (also
known as "Mch3 ," "ICE-LAP3" "CMH-1 "), Caspase-8 (also
known as "FLICE;" "MACH;" "Mch5"), Caspase-9 (also
known as "I CE-LAP6;" "Mch6"), Caspase-10 (also known as
"Mch4," "FLICE-2").
The phrase "caspase-dependent apoptosis" as used herein
refers to an apoptosis pathway that involves caspases. In a
caspase-dependent apoptosis pathway, mature Omi/HtrA2
comprising the tetrapeptide motif "AVPS" which binds to
x-chromosome linked InhibitorofApoptosis Protein (XIAP),
and causes caspase activation, which results in apoptosis.
The phrase "caspase-independent apoptosis" as used
herein refers to apoptosis pathway that does not involves
caspases. Instead, Omi/HtrA2 behaves like a serine protease
exhibiting proteolytic activity. When Omi/HtrA2 functions as
a protease, it proteolytically cleaves specific protein substrates leading to apoptosis.
The term "apoptosis inhibiting compound" as used herein
refers to an agent that can reduce apoptosis by a detectable
amount by acting on a pathway involved in apoptosis. The
agent can act by inhibiting or blocking a particular step in the
apoptotic pathway, for example by blocking or inhibiting the
activity of protein involved in the pathway, such as inhibiting
the activity of Omi/HtrA2. The apoptotic pathway includes
both caspase-dependent apoptosis, as well as caspase-independent apoptosis. In a preferred embodiment, the apoptosis
inhibiting compound acts on the caspase-independent apoptosis pathway to reduce or inhibit apoptosis by a detectable
amount. Examples of apoptosis inhibiting compounds,
include, but are not limited to those structures shown in FIG.
la, FIG. 2a, FIG. 3a, and FIG. 4a. Preferred apoptosis inhibiting compounds are referred to as "Ucf-101" (shown in FIG.
lb), "Ucf-102" (shown in FIG. 2b), "Ucf-103" (shown in
FIG. 3b) and "Ucf 104" (shown in FIG. 4b). A particularly
preferable apoptosis inhibiting compound is Ucf 101. Also
within the scope of the invention are the use of combinations
and mixtures of apoptosis inhibiting compounds, for
example, a mixture comprising Ucf-101 and Ucf-102; Ucf101, Ucf-102, and Ucf-103; or Ucf-101, Ucf-102, Ucf-103
and Ucf 104, or any combinations thereof.
The term "inhibit" or "inhibiting" as used herein refers to a
measurable reduction of apoptotic activity. Preferably a
reduction of activity of at least about 20%. More preferably
the reduction of activity is about 30%, 40%, 50%, 60%, 80%,
90% and even more preferably, about 100%.
The term "modulate" or "modify" are used interchangeably herein and refer to an alleviation of at least one target
protein or gene involved in the caspase-independent pathway for apoptosis. Such that apoptosis is inhibited or reduced.
A target protein can be for example, Omi/Htr2A. Modification of the Omi/Htr2A may occur when an apoptosis inhibiting compound interacts with Omi/Htr2A an alters the functional activity of Omi/Htr2A. A modification in apoptosis can
be assessed by monitoring cell blebbing DNA fragmentation,
and the like.
The phrase "a disorder associated with Omi/Htr2A activity" or "a disease associated with Omi/Htr2A activity" as
used herein refers to any disease state associated with the
expression of Omi/Htr2A. Examples include but are not limited to kidney failure, ischemia-reperfusion injury, heart failure, neurodegeneration disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease and
amytrophic lateral sclerosis; inflanimation; osteoarthritis;
human immunodeficiency virus); bacterial infection, cell
proliferative disorders, cancers, and diabetes.
The term "subject" as used herein refers to any living
organism in which an immune response is elicited. The term

DETAILED DESCRIPTION
The practice of the present invention employs, unless otherwise indicated, conventional methods of virology, microbiology, molecular biology and recombinant DNA techniques
within the skill of the art. Such techniques are explained fully
in the literature. (See, e.g., Sambrook, et al. Molecular Cloning: A Laboratory Manual (Current Edition); DNA Cloning:
A Practical Approach, Vol. I & II (D. Glover, ed.); Oligonucleotide Synthesis (N. Gait, ed., Current Edition); Nucleic
Acid Hybridization (B. Hames & S. Higgins, eds., Current
Edition); Transcription and Translation (B. Hames & S. Higgins, eds., Current Edition); CRC Handbook of Parvoviruses,
Vol. I & II (P. Tijessen, ed.); Fundamental Virology, 2nd
Edition, Vol. I & II (B. N. Fields and D. M. Knipe, eds.))
So that the invention is more clearly understood, the following terms are defined:
The term "apoptosis" as used herein refers to the art recognized use of the term for an active process of programmed
cell death characterized by morphological changes in the cell.
Apoptosis is characterized by membrane blebbing and
nuclear DNA fragmentation. Apoptosis can occur via two
pathways, the caspase-dependent pathway, where involves
caspases where Omi/HtrA2 interacts with an inhibitor of
apoptosis protein (IAP) and activates the caspase pathway.
Alternatively, apoptosis can occur via the caspase-independent pathway, where Omi/HtrA2 acts as a serine protease and
does not involve caspases.
The phrase "inhibitor of apoptosis protein (IAP)" as used
herein referres to the art recognized use of the phrase for a
protein that contains at least one copy ofBaculovirus IAP of
a repeat (BIR) domain and suppresses apoptosis when overexpressed and is known to bind and inhibit caspases.
The term "zymogen" as used herein refers to the inactive
proform of an enzyme e.g. a caspase, which is typically
activated by proteolysis.
The term "caspase" as used herein refers to a cysteine
protease that specifically cleaves proteins after Asp residues.
Caspases are initially expressed as zymogens, in which a
large subunit is N-terminal to a small subunit. Caspases are
generally activated by cleavage at internal Asp residues.
Caspases are found in a myriad of organisms, including
human, mouse, insect (e.g., Drosophila), and other invertebrates (e.g., C. elegans). The caspases include, but are not
limited to, Caspase-1 (also known as "ICE"), Caspase-2 (also
known as "ICH-1"), Caspase-3 (also known as "CPP32,"
"Yama," "apopain"), Caspase-4 (also known as "ICE.rezIJ';
"TX," "ICH-2"), Caspase-5 (also known as "ICE.rezIJ';
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subject includes, but is not limited to, humans, nonhuman
primates such as chimpanzees and other apes and monkey
species; farm animals such as cattle, sheep, pigs, goats and
horses; domestic mammals such as dogs and cats; laboratory
animals including rodents such as mice, rats and guinea pigs,
and the like. The term does not denote a particular age or sex.
Thus, adult and newborn subjects, as well as fetuses, whether
male or female, are intended to be covered.
The invention is described in more detail in the following
sections:
I. Apoptosis and Omi/HtrA2
In one aspect, the invention pertains to reducing, inhibiting,
preventing or altering apoptosis, particularly caspase-independent apoptosis. Apoptosis or programmed cell death was
originally described by Kerr et al., in 1972 (Kerr, et al. (1972)
Br J Cancer, 26, 239-57), as a new cell-autonomous mechanism of death aimed at removing damaged, mutated or aged
cells. Mitochondria, are directly linked to the process of apoptosis to the extent that they are now termed "killer
organelles" (Ravagnan, et al. (2002) J Cell Physiol, 192,
131-7). Mitochondria contain several proteins in their intermembrane space which are released in response to pro-apoptotic stimuli. These diverse proteins include cytochrome c,
AIF, Smac/Diablo, endonuclease G and Omi/HtrA2 (See e.g.,
Van Loo, et al. (2002) Cell Death Differ, 9, 1031-42). Each of
these proteins has a distinct function but they are all proapoptotic and, invariably, their release from the mitochondria
induces cell death. Omi/HtrA2, the most recent member of
this group, was originally isolated and characterized as a new
members of the stress-signaling pathway (Faccio, et al.
(2000) J. Biol. Chem., 275, 2581-8). Omi/HtrA2 has high
sequence homology to bacterial HtrAs, proteins that act as
chaperones at normal temperatures and as proteases at
elevated temperatures to remove damaged or denatured proteins (Fallen, et al. (1997) Mal. Microbial., 26, 209-21).
Omi/HtrA2 is a human serine protease that has extensive
homology to bacterial high temperature requirement A
(HtrA) proteins (Faceio et al. (2000) J. Biol. Chem. 275,
2581-2588; and Gray et al. (2000) Eur., J. Biochem. 267,
5699-5710). Bacterial HtrAs have a dual function, acting as
chaperones at normal temperatures and as proteases at
elevated temperatures and removing damaged or denatured
proteins, allowing the recovery and survival of bacteria following stress (Fallen et al. (1997) Mal. Microbial. 26, 209221; and Spiess et al. (1999) Cell 97, 339-347).
Mammalian Omi/HtrA is a ubiquitous protein, although
tissue-specific alternatively spliced forms have been reported
(Gray et al. (2000) Eur., J. Biochem. 267, 5699-5710; and
Faccio et al. (2000) Genomics 68, 343-347). Recent studies
described Omi as a mitochondrial protein that upon induction
of apoptosis is released to the cytoplasm where it binds XIAP
(X chromosome-linked inhibitor of apoptosis protein) resulting in caspase-9 activation (Suzuki et al. (2001) Mal. Cell. 8,
613-621; Hegde et al. (2002) J. Biol. Chem. 277, 432-438;
Martins eta!. (2002)J. Biol. Chem. 277, 439-444; Verhagen et
al. (2002) J. Biol. Chem. 277, 445-454; and van Loo et al.
(2002) Cell Death Differ. 9, 20-26). In this regard, Omi
resembles Smac/DIABLO, which also binds IAPs and as a
result activates caspase-9 (Flu et al. (2000) Cell I 02, 33-42;
and Verhagen et al. (2000) Cell 102, 43-53).
Omi/HtrA2 protein is synthesized as a precursor that is
processed in the mitochondria to produce the mature protein.
This processing exposes an internal tetrapeptide motif,
AVPS, at the amino terminus. A similar motif is found in all
!AP-binding proteins, including the Drosophila Grim,
Reaper, Hid, and Sickle (Chen et al. (1996) Genes Dev. 10,
1773-1782; Vucic et al. (1997) Proc. Nail. Acad. Sci. U.S.A.

94, 10183-10188; Vucic et al. (1998) Mal. Cell. Biol. 18,
3300-3309; and Srinivasula et al. (2002) Cur. Biol. 12, 125130).
Omi/HtrA2 is present in the mitochondria and is released
to the cytoplasm upon induction ofapoptosis. In this capacity,
Omi/HtrA2 is unique both in its structure as well as its function. In the cytoplasm, Omi/HtrA2 can induce apoptosis
through a caspase-dependent as well as in a caspase-independent pathway.
Omi/HtrA2 belongs to a family of mammalian serine proteases; its proteolytic activity is necessary for auto-processing to expose the AVPS motif. Furthermore, Omi/HtrA2 can
also induce apoptosis in a manner that does not depend on the
AVPS motif but depends entirely on its ability to function as
a protease (Suzuki, et al. (200l)Mol. Cell., 8, 613-21; Hegde,
et al. (2002) J Biol Chem, 277, 432-8; Martins, et al. (2002)J.
Biol. Chem., 277, 439-44; and Verhagen, et al. (2002) J. Biol.
Chem., 277, 445-54). Thus suggests specific substrates for
Omi/HtrA2 may exist and their cleavage (whether this leads
to activation of a precursor or a destruction of a protein) may
be a part of the apoptotic process. One other member of
family of proteases is L56/HtrA1, is a serine protease that is
overexpressed in osteoathritic cartilage (Hu, et al. (1998) J.
Biol. Chem., 273, 34406-12) and is also repressed in fibroblasts following SV40 infection (Zumbrunn, et al. (1996)
FEBSLett., 398, 187-92). ThesimilaritybetweenOmi/HtrA2
and other proteins is restricted to their carboxyl terminus
which includes the proteolytic domain and PDZ motif while
the amino termini of the two proteins are different (Faccio, et
al. (2000) J. Biol. Chem., 275, 2581-8). Unlike Omi/HtrA2,
which remains intracellular, L56/HtrA1 is secreted (Faccio,
et al. (2000) supra; and Hu, et al. (1998) J. Biol. Chem., 273,
34406-12).
When Omi/HtrA2 induces apoptosis in a caspase-independent pathway, it does so by relying entirely on its ability to
function as a serine protease (Suzuki et al. (2001) Mal. Cell.
8, 613-621; Hegde et al. (2002) J. Biol. Chem. 277, 432-438;
and Verhagen et al. (2002) J. Biol. Chem. 277, 445-454).
Neitherthe mechanism nor the significance of this function of
Omi/HtrA2 is clearly understood.
Structurally, Omi/HtrA2 is a 458 amino acid polypeptide
that was originally isolated as an interactor of Mxi2 kinase
(Faccio, et al. (2000) J. Biol. Chem., 275, 2581-8). It was
subsequently identified as an interactor of presenilin, a protein found mutated in some cases of Alzheimer's disease
(Gray, et al. (2000)EurJ Biochem, 267, 5699-710). There are
three distinct domains in the Omi/HtrA2 protein: a catalytic
domain, a PDZ domain and an amino terminal domain (see
FIG. 6). The amino-terminal domain carries a mitochondrial
targeting sequence (MTS) and three copies of a motif
PRAAXXTXX (SEQ ID No:l), where Xis any amino acid.
The function of this motif is not yet known. This amino
terminal domain of Omi (aa 1-133) is cleaved through an
intra-molecular reaction to create the mature Omi/HtrA2 protein. The mature Omi/HtrA2 has a new exposed amino terminal sequence (AVPS) that is similar to the sequence present
in other known inhibitors of apoptosis (IAP)-binding proteins
(See Table 1). This family of proteins includes the only other
known IAP binding protein Smac/DIABLO (Du, et al. (2000)
Cell, 102, 33-42; and Verhagen, et al. Cell, 102, 43-53), as
well as three Drosophila proteins Reaper (Vucic, et al. (1997)
Proc. Natl. Acad. Sci. USA, 94, 10183-8; and Vucic, et al.
(1997) Mal Cell Biol, 17, 667-76), Hid (Vucic, et al. (1998)
Mal Cell Biol, 18, 3300-9) and Grim (Chen, et al. (1996)
Genes Dev, 10, 1773-82). Besides the presence of the IAPbinding motif, no other similarity is found between these
proteins.
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TABLE 1

ing: A Laboratory Manual, Cold Spring Harbor Press, 1989).
Typically, homologous polynucleotide sequences can be confirmed by hybridization under stringent conditions, as is
known in the art. For example, using the following wash
conditions: 2xSSC (0.3 M NaCl, 0.03 M sodium citrate, pH
7.0), 0.1 % SDS, room temperature twice, 30 minutes each;
then 2.times.SSC, 0.1 % SDS, 50° C. once, 30 minutes; then
2xSSC, room temperature twice, 10 minutes each, homologous sequences can be identified which contain at most about
25-30% basepair mismatches. More preferably, homologous
nucleic acid strands contain 15-25% basepair mismatches,
even more preferably 5-15% basepair mismatches.
The term "homology" or "identity" or "homologous" as
used herein refers to the percentage oflikeness between molecules. To determine the homology or percent identity of two
amino acid sequences or of two nucleic acid sequences, the
sequences are aligned for optimal comparison purposes (e.g.,
gaps can be introduced in one or both of a first and a second
amino acid or nucleic acid sequence for optimal alignment
and non-homologous sequences can be disregarded for comparison purposes). In a preferred embodiment, the length of a
reference sequence aligned for comparison purposes is at
least 30%, preferably at least 40%, more preferably at least
50%, even more preferably at least 60%, and even more
preferably at least 70%, 80%, or 90% of the length of the
reference sequence. The amino acid residues or nucleotides at
corresponding amino acid positions or nucleotide positions
are then compared. When a position in the first sequence is
occupied by the same amino acid residue or nucleotide as the
corresponding position in the second sequence, then the molecules are identical at that position (as used herein amino acid
or nucleic acid "identify" is equivalent to amino acid or
nucleic acid "homology"). The percent identify between the
two sequences is a function of the number of identical positions shared by the sequences, taking into account the number
of gaps, and the length of each gap, which need to be introduced for optimal alignment of the two sequences.
The comparison of sequences and determination of percent
identify between two sequences can be accomplished using a
mathematical algorithm. For example, the percent identity
between two amino acid sequences can be determined using
the Needleman and Wunsch (1970) J. Mal. Biol. (48):444453) algorithm which has been incorporated into the GAP
program in the GCG software package (available at http://
www.gcg.com), using either a Blossom 62 matrix or a
PAM250 matrix, and a gap weight of 16, 14, 12, 10, 8, 6, or 4
anda length weight of 1, 2, 3, 4, 5, and 6. In another example,
the percent identify between two nucleotide sequences is
determined using the GAP program in the GCG software
package (available at http://www.gcg.com), using a NWSgapdna.CMP matrix and a gap weight of 40, 50, 60, 70, or 80
and a length weight of 1, 2, 3, 4, 5, or 6. In yet another
example, the percent identify between two amino acid or
nucleotide sequences is determined using the algorithm ofE.
Meyers and W. Miller (CABIOS, 4:11-17 (1989)) which has
been incorporated into the ALIGN program (version 2.0),
using a PAMl 20 weight residue table, a gap length penalty of
12 and a gap penalty.
III. Omi/HtrA2 and Tubular Cell Death
In one aspect, the invention pertains to inhibiting tubular
cell death by modifying apoptosis, preferably by modifying
caspase-independent apoptosis. In a particularly preferred
embodiment, the methods and compositions of the invention
can be used for acute renal failure (ARF).
ARF is a serious medical problem that occurs in 5% of all
hospitalized patients. The prognosis of ARF is poor, has
remained unchanged over the past three decades, and carries

Comparison of known !AP-binding motifs found in two
mammalian (Omi/HtrA2 and Smac/DIABLO) and
three Drosophila proteins
Omi/HtrA2
Smac/Diablo
Reaper
Hid
Grim

AVPSPPPA
AVPIAQKS
AVAFYIPD
AVPFYLPE
AIAYFIPD
10

Omi/HtrA2 mRNA is expressed ubiquitously, and the gene
is localized on human chromosome 2p12. Omi/HtrA2 interacts with Mxi2, an alternatively spliced form of the p38
stress-activated kinase and, when made in a heterologous
system, shows proteolytic activity against a non-specific substrate ~-casein. The proteolytic activity of Omi/HtrA2 is
markedly up-regulated in the mouse kidney following
ischemia/reperfusion. (See Examples)
Therefore, Omi/HtrA2 promotes cell death via two different pathways: one that relies on IAP binding and inhibition
and involves caspase activation, and the second which
depends on its proteolytic activity and is caspase-independent. (See FIG. 5)
Alternative forms of Omi/HtrA2 are also within the scope
of the invention and include alternative splice forms and their
encoded polypeptides. In one embodiment, the alternatively
spliced form of Omi/HtrA2 is D-Omi that is expressed predominantly in the kidney (See Examples). To identify the
origin of this alternatively spliced form, the genomic locus of
Omi/HtrA2 was characterized and found to be present on the
human chromosome 2p 12. Omi gene consists of eight exons,
two of them are absent in the kidney specific D-Omi. D-Omi
is not able to bind to the Mxi2 protein due to its modified PDZ
domain. Furthermore, D-Omi has no detectable proteolytic
activity when tested against ~-casein, a generic substrate.
D-Omi lacks the amino acid sequence encoded by two
exons and is structurally quite distinct from Omi/HtrA2. It
has a modified PDZ domain and shows no detectable proteolytic activity. The data shown in the Examples section
suggest that D-Omi may have a unique function, different
from Omi/HtrA2, in the tissues where it is expressed. D-Omi
may also function in apoptosis and it may have role in modulating cellular events following tubular cell injury, such as
renal tubule cell injury.
Variants of the Omi/HtrA2 nucleic acid molecules and the
proteins they encode are also within the scope of the invention, these include natural variants (e.g., polymorphisms,
splice variants or mutants) and those produced by genetic
engineering (e.g., substitutions, deletions or addition ofresidues ). Many methods for generating mutants have been
developed (see generally, Ausubel et al., supra). Preferred
methods include alanine scanning mutagenesis and PCR generation of mutants using an oligonucleotide containing the
desired mutation to amplify mutant nucleic acid molecules.
Variants generally have at least 70% or 75% nucleotide identity to the native sequence, preferably at least 80%-85%, and
most preferably at least 90%, 92%, 93%, 94%, 95%, 96%,
97%, 98% or 99% nucleotide identity.
Further, a nucleotide variant will typically be sufficiently
similar in sequence to hybridize to the reference sequence
under moderate or stringent hybridization conditions. For
nucleic acid molecules over about 500 bp, stringent conditions include a solution comprising about 1 MNa+ at25 to 30°
C. below the Tm; e.g., 5xSSPE, 0.5% SDS, at 65 C.; see
Ausubel et al., Current Protocols in Molecular Biology,
Greene Publishing, 1995; Sambrook et al., Molecular Clan-
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a high mortality rate of about 50%. AlthoughARF is the result
of many causes, the most common cause is injury to the renal
tubular epithelial cells (RTEC).
The invention relates to the role of Omi/HtrA2 in the apoptotic cell death that occurs in RTEC, as well as the molecular
events that follow its activation leading to apoptosis. By
blocking the activity of Omi/HtrA2 using a specific inhibitor,
a new approach to protect and maintain cell viability is available.
The cell death that follows renal injury is both apoptotic as
well as necrotic (Lieberthal, et al. (1998) Semin Nephrol, 18,
505-18). The relative contribution of these two forms of cell
death to tubular necrosis is not yet known. It depends both on
the nature as well as severity of insult. Severe injury (e.g.
ishcedmic injury) usually triggers necrosis whereas milder
insults to the kidney cause apoptotic death of the RTEC.
Necrosis is difficult to prevent but apoptosis can potentially
be modulated to maintain cell viability. Therefore, identifying the different components of the apoptotic pathway, especially the ones that play a major role in kidney, provides new
information on the apoptotic process. These new components
can also provide specific and novel targets for intervention to
help patients with acute renal failure.
Most of the previous studies on tubular apoptosis have
focused on the role of caspases and their activation and have
utilized caspase-specific inhibitors in an attempt to inhibit
apoptosis and protect tubular cells from ischemic as well as
toxic insults (See e.g., Ueda, et al. (2000) Am J Med, 108,
403-15; and Ueda, et al. (2000) Nephrol Dial Transplant, 15,
318-23). Omi/HtrA2 is a pro-apoptotic protease and is the
only protein identified thus far that is able to cause apoptosis
in a caspase-dependent as well as caspase-independent manner. The caspase-independent pathway is not yet clearly
understood but relies on the ability of Omi/HtrA2 to function
as a serine protease.
Table 2 lists known inducers of apoptosis of tubular cells in
acute renal failure. Caspases have been shown to be activated
both by ischemic as well as cytotoxic insults to cultured
RTECs (Lau, et al. (1999) Kidney Int, 56, 1295-8; Hortelano,
et al. (2000) J Am Soc Nephrol, 11, 2315-23; van de Water, et
al. (2000)J Biol Chem, 275, 25805-13. 2000; and Kaushal, et
al. (2001) Kidney Int, 60, 1726-36) as well as kidney cells in
vivo (Daemen, et al. (2001) Transplantation, 71, 778-84; Shi,
et al. (2000) Am J Physiol, 279, F509-l 7; Sano, et al. (2000)
Kidney Int, 57, 1560-70; and Bonventre, (1998) Kidney &
Blood Pressure Research, 21, 226-9). Furthermore, inhibition
of caspases ameliorates ischemia-reperfusion injury in the
kidney (Daemen, et al. (1999) J Clin Invest, 104, 541-9).

hours after ischemia/reperfusion as well as in MPT cells
treated with antimycin or cisplatin (inducers of apoptosis).
The amount of Omi/HtrA2 protein increases dramatically
after ischemic or chemical injury in the mouse kidneys or
MPT cells. Furthermore, inhibiting the proteolytic activity of
Omi/HtrA2 using the ucf-101 inhibitor protects MPT cells
from cisplatin-induced apoptosis.
Though not bound by any theory, Omi/HtrA2 may exert its
caspase-independent effect by proteolytic cleavage of potential substrates leading to the destruction and removal of the
substrates as part of this process. Alternatively, Omi/HtrA2,
through specific proteolytic cleavage, might activate precursor proteins that are part of the caspase-independent apoptotic
process.
IV. Inhibitors
In one aspect, the invention pertains to using inhibitors of
caspase-independent apoptosis. In order to investigate the
caspase-independent mechanism of apoptosis initiated by
Omi/HtrA2, specific inhibitors of its proteolytic activity were
isolated. One such family of synthetic compounds was identified and described in the Examples section. In one embodiment, the apoptosis inhibiting compound include the class of
heterocyclic compounds referred to as 1,3 diphenyl-5-(substituted)-2-thioxo-dihydropyrimidine-4,6-dione derivatives.
In a preferred embodiment, the apoptosis inhibiting compound has the general structure shown in FIG. la, where R 1 ,
depicts the various side chains which can include, but are not
limited to a nitro group, a carboxy group, a hydroxide, an
aliphatic group, an aromatic group, an acyl group, an alkoxy
group, an alkylene group, an alkenylene group, an alkynylene
group, a hydroxycarbonylalkyl group, an anhydride, an
amide, an amine, and a heterocyclic aromatic group. In a
preferred embodiment, the apoptosis inhibiting compound
has the structure shown in FIG. lb and is referred to as
"ucf-101".
In another embodiment, the apoptosis inhibiting compound has a general structure shown in FIG. 2a, where R 1 is
a nitro group, a carboxy group, a hydroxide, an aliphatic
group, an aromatic group, an acyl group, an alkoxy group, an
alkylene group, an alkenylene group, an alkynylene group, a
hydroxycarbonylalkyl group, an anhydride, an amide, an
amine, and a heterocyclic aromatic group. In a preferred
embodiment the apoptosis inhibiting compound has the structure shown in FIG. 2b and is referred to as "ucf-102".
In another embodiment, the apoptosis inhibiting compound has the general structure shown in FIG. 3a, where R 1 is
a nitro group, a carboxy group, a hydroxide, an aliphatic
group, an aromatic group, an acyl group, an alkoxy group, an
alkylene group, an alkenylene group, an alkynylene group, a
hydroxycarbonylalkyl group, an anhydride, an amide, an
amine, and a heterocyclic aromatic group. In preferred
embodiment, the apoptosis inhibiting compound has the
structure shown in FIG. 3b and is referred to as "ucf-103."
In another embodiment, the apoptosis inhibiting compound has the general structure shown in FIG. 4, where R 1 is
a nitro group, a carboxy group, a hydroxide, an aliphatic
group, an aromatic group, an acyl group, an alkoxy group, an
alkylene group, an alkenylene group, an alkynylene group, a
hydroxycarbonylalkyl group, an anhydride, an amide, an
amine, and a heterocyclic aromatic group. In preferred
embodiment, the apoptosis inhibiting compound has the
structure shown in FIG. 4b and is referred to as "ucf-104".
These class ofheterocyclic compounds showed significant
and specific activity against the protease in an in vitro assay.
The compound from this family, which exhibited the highest
activity against Omi/HtrA2 is ucf-101. The results clearly
showed ucf-101 had a profound effect on the activity of
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Potential causes of apoptosis of tubular cells in acute renal failure
The default pathway Grow factor deficiency: Rapamycin
Loss of cell-matrix adhesion, Loss of cell-cell
of apoptosis
adhesion
Renal tubular
Ischemia!hypoxia: Oxidant stress
cell injury
Phannacologic agents: Cisplatin, Aminoglycosides,
Amphotericin B
Fas-FasL: TNF-a-TNF Receptor type 1,
Receptor-ligand
Angiotensin 11-angiotensin II receptor type
interactions
2 (ATR2)

Omi/HtrA2 plays a role in the apoptosis that occurs in
RTECs following renal injury. The data in the Examples
section shows that Omi/HtrA2 is predominantly expressed in
the proximal tubular cells in both human and mouse kidneys.
This area of the kidney is most susceptible to ischemic injury.
The protein level of Omi/HtrA2 increased dramatically 24
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Omi/HtrA2 and could substantially inhibit its ability to
induce caspase-independent apoptosis in caspase-9 (-/-)null
fibroblasts. The results clearly showed ucf-101 had a profound effect on the activity ofOmi/HtrA2 and could substantially inhibit its ability to induce caspase-independent apoptosis in caspase-9 (-/-)null fibroblasts.
U cf-101 naturally fluoresces and easily enters mammalian
cells, allowing its use in in vivo experiments. The ucf-101
inhibitor can therefore be used as a tool to dissect the two
different activities (caspase-dependent versus caspase-independent) ofOmi and their respective contribution to apoptosis in various biological settings. Furthermore, ucf-101, or a
similar compound, may be useful as an anti-apoptotic drug
that would specifically target caspase-independent cell death
under clinical conditions.
V. Omi/HtrA2 Substrates
In one aspect, the invention pertains to identifying substrates involved in caspase-independent apoptosis. In particular, the identification of substrates of Omi/HtrA2. To identify
Omi/HtrA2 substrates an assay for substrates can be performed. In general, assays are designed to evaluate apoptotic
pathway activation (e.g., caspase protein processing, caspase
enzymatic activity protease activity, cell viability, cell morphology changes, DNA laddering, and the like). In any of the
assays, a statistically significant increase or decrease compared to a proper control is indicative of enhancement or
inhibition. In a preferred embodiment, apoptosis is monitored
by an electrophoresis method (e.g., 2D gel electrophoresis),
where the presence, absence or disappearance if a protein is
measured. In such an assay, cell extracts are incubated with
recombinant Omi/HtrA2 (test sample) and without Omi/
HtrA2 (control sample). After incubation, the cell extracts are
examined by electrophoresis (e.g., 2D electrophoresis). Typically, the presence of a protein in the control sample, and its
subsequent disappearance (or the degradation into smaller
fragments) in the test sample, identifies the presence of a
specific Omi/HtrA2 substrate in the cell extract. The disappearance of the protein band indicates that the protein is a
specific substrate of Omi/HtrA2 which has been degraded by
the protease activity ofOmi/HtrA2.
Using this assay, the data shown in the Examples section
identifies two substrates for Omi/HtrA2. In one embodiment,
the Omi/HtrA2 substrate is the 14-3-3 protein. In another
embodiment, the Omi/HtrA2 substrate is annexin V. The data
shows that the two polypeptides were specifically cleaved by
Omi/HtrA2 and their degradation was inhibited by the specific inhibitor ucf-101. Annexin V and 14-3-3 proteins were
shown to be involved in both apoptosis and intracellular signaling.
VI. Screening for Inhibitor or Enhancers
In one aspect, the invention pertains to identifying inhibitors of apoptosis, particularly inhibitors of caspase-independent apoptosis. In particular, the identification of inhibitors of
Omi/HtrA2. Candidate inhibitors may be isolated or procured
from a variety of sources, such as bacteria, fungi, plants,
parasites, libraries of chemicals, peptides or peptide derivatives, antibodies, and the like. Inhibitors may also be rationally designed, based on the protein structures determined
from X-ray crystallography.
Without wishing to be bound to a particular theory or held
to a particular mechanism, an inhibitor may act by preventing
Omi/HtrA2 release from the mitochondria, interfering with
Omi/HtrA2 binding to an IAP, inhibiting Omi/HtrA2 protease activity, or by other mechanisms. If the caspase dependent pathway is involved, the inhibitor may act to prevent
caspase activity. Alternatively, if the capase-independent
pathway is involved, the inhibitor may inhibit the proteolytic

activity ofOmi/HtrA2 when it acts as a serine protease Inhibitors may include small molecules (organic molecules), peptides, polypeptides, and antibodies, for example. In one
embodiment, the inhibitors prevent apoptosis. Inhibitors
should have a minimum of side effects and are preferably
non-toxic.
Screening assays for inhibitors will vary according to the
type of inhibitor and the nature of the activity that is being
affected. Assays may be performed in vitro or in vivo. In
general, assays are designed to evaluate apoptotic pathway
activation (e.g., caspase protein processing, caspase enzymatic activity, serine protease activity cell viability, cell morphology changes, DNA laddering, and the like). In any of the
assays, a statistically significant increase or decrease compared to a proper control is indicative of enhancement or
inhibition. In a preferred embodiment, apoptosis is monitored
by a fluorescent method. Typically, an increase in cell viability as compared to a control indicates the presence of an
inhibitor, while a decrease in cell viability as compared to a
control indicates the presence of an enhancer.
For a caspase-independent in vitro assay, a substrate of
Omi/HtrA2 is fluorescently labeled with fluorescent marker
(e.g. FITC), and fluorescently labeled substrate is incubated
with recombinant Omi/HtrA2 (e.g., MPB-Omi 134_458 ). The
fluorescent activity of substrate is measured using a fluorescent microscopy or a fluorescemeter. As the Omi/HtrA2 protease acts on the substrate, a change in the fluorescence can be
measured. Using this fluorescent assay, inhibitor and enhancers ofOmi/HtrA2 can be used and the change in fluorescence
in the presence of an inhibitor or enhancer can be measured.
To facilitate detection using the fluorescent method with a
substrate labeled with a fluorescent marker (e.g., FITC, and
the like) the substrate can be examined by fluorescence
microscopy. Candidate compounds may be obtained from a
variety of sources. For example, they may be produced
recombinantly, purified from a natural source, or synthesized.
Alternatively, candidate molecules may be identified by
screening a library of compounds such as those available
form Nanoysn. The preferred compound will be one that is
able to inhibit apoptosis, preferably caspase-independent
apoptosis. The candidate compounds can be at least partially
purified, and most preferably, candidate compounds will be
purified to near homogeneity. Appropriate controls depend
upon the source of the candidate compound and might
include, for example, extracts from cells transfected with
control vector, or storage or reaction buffers.
For a caspase-dependent in vitro assay detecting inhibitors
and enhancers of caspase-mediated apoptosis can be performed by examining the effect of a candidate compound on
the activation of an initiator caspase (e.g., caspase 9) or an
effectorcaspase (e.g., caspases 3-7). Briefly, procaspase 9, an
IAP, cytochrome c, dATP, and an Omi peptide, polypeptide,
functional variant, or functional equivalent are provided. The
processing of caspase-9 into two subunits is assayed. Alternatively, caspase-9 enzymatic activity is monitored by adding
procaspase-3, procaspase-7, or other effector caspases to the
reaction mix and monitoring the activation of these caspases,
for example, either via subunit formation or via cleavage of a
substrate (e.g., acetyl DEVD-aminomethyl coumarin (amc),
lamin, PRPP, PARP, and the like). Typically, an increase in
processing to subunits indicates the presence of an enhancer,
while a decrease in processing to subunits indicates the presence of an inhibitor.
Also, for caspase-dependent apoptosis a candidate compound may be used for binding assays. A candidate compound may be added to a binding reaction with an Omi
binding molecule and recombinant Omi/HtrA2 peptide or
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polypeptide, and its ability to inhibit Omi/HtrA2 binding to
(BASF, Parsippany, N.J.) or phosphate buffered saline (PBS).
an Omi-binding molecule can be determined by comparing
In all cases, the composition must be sterile and should be
binding in the presence or absence of a candidate compound.
fluid to the extent that easy syringability exists. It must be
In certain circumstances, such assays will detect displacestable under the conditions of manufacture and storage and
ment or inhibition of binding of an Omi-binding molecule
must be preserved against the contaminating action of microfrom an Omi peptide or polypeptide.
organisms such as bacteria and fungi. The carrier can be a
In vivo assays are typically performed in cells transfected
solvent or dispersion medium containing, for example, water,
either transiently or stably with an expression vector containethanol,
polyol (for example, glycerol, propylene glycol, and
ing an Omi/HtrA2 nucleic acid molecule such as those
10 liquid polyethylene glycol, and the like), and suitable mixdescribed herein. These cells may be used to measure caspase
tures thereof. The proper fluidity can be maintained, for
processing, caspase substrate turnover, enzymatic activity of
example, by the use of a coating such as lecithin, by the
effector caspases, or apoptosis in the presence or absence of a
candidate compound. When assaying apoptosis, a variety of
maintenance of the required particle size in the case of dismethods of cell analyses may be used, including, for example,
15 persion and by the use of surfactants. Prevention of the action
fluorescent spectroscopy and electro-proteins dye staining
of microorganisms can be achieved by various antibacterial
and microscopy to examine cell viability, nucleic acid fragand
antifungal agents, for example, parabens, chlorobutanol,
mentation, porosity of the cells, and membrane blebbing.
phenol,
ascorbic acid, thimerosal, and the like. In many cases,
A variety of methodologies exist that can be used to invesit will be preferable to include isotonic agents, for example,
tigate the effect of a candidate compound. Such methodolo20
gies are those commonly used to analyze enzymatic reactions
sugars, polyalcohols such as manitol, sorbitol, sodium chloand include, for example, SDS-PAGE, 2D-gel electrphoresis,
ride in the composition. Prolonged absorption of the injectfluorescent spectroscopy, fluorescent microscopy, HPLC
able compositions can be brought about by including in the
analysis, autoradiography, chemiluminescence, chromogecomposition an agent which delays absorption, for example,
nic reactions, and immunochemistry (e.g., blotting, precipi25 aluminum monostearate and gelatin.
tating, etc.).
Sterile injectable solutions can be prepared by incorporatVII Pharmaceutical Compositions
ing the active compound (e.g., a receptor protein or antiThe apoptosis inhibiting compound can be incorporated
receptor antibody) in the required amount in an appropriate
into pharmaceutical compositions suitable for administration
solvent with one or a combination of ingredients enumerated
to a subject, e.g., a human. Such compositions typically com30
prise the apoptosis inhibiting compound and a pharmaceutiabove, as required, followed by filtered sterilization. Genercally acceptable carrier.
ally, dispersions are prepared by incorporating the active
As used herein the language "pharmaceutically acceptable
compound into a sterile vehicle which contains a basic discarrier" is intended to include any and all solvents, dispersion
persion medium and the required other ingredients from those
media, coatings, antibacterial and antifungal agents, isotonic
35 enumerated above. In the case of sterile powders for the
and absorption delaying agents, and the like, compatible with
preparation of sterile injectable solutions, the preferred methpharmaceutical administration. The use of such media and
ods of preparation are vacuum drying and freeze-drying
agents for pharmaceutically active substances is well known
which yields a powder of the active ingredient plus any addiin the art. Except insofar as any conventional media or agent
tional desired ingredient from a previously sterile-filtered
is incompatible with the active compound, such media can be
40 solution thereof.
used in the compositions of the invention. Supplementary
Oral compositions generally include an inert diluent or an
active compounds can also be incorporated into the compoedible carrier. They can be enclosed in gelatin capsules or
sitions. A pharmaceutical composition of the invention is
compressed into tablets. For oral administration, the agent
formulated to be compatible with its intended route ofadmincan be contained in enteric forms to survive the stomach or
istration. Examples of routes of administration include
45 further coated or mixed to be released in a particular region of
parenteral, e.g., intravenous, intradermal, subcutaneous, oral
the GI tract by known methods. For the purpose of oral
(e.g., inhalation), transdermal (topical), transmucosal, and
therapeutic administration, the active compound can be
rectal administration. Solutions or suspensions used for
incorporated with excipients and used in the form of tablets,
parenteral, intradermal, or subcutaneous application can
troches, or capsules. Oral compositions can also be prepared
include the following components: a sterile diluent such as
50 using a fluid carrier for use as a mouthwash, wherein the
water for injection, saline solution, fixed oils, polyethylene
compound in the fluid carrier is applied orally and swished
glycols, glycerine, propylene glycol or other synthetic soland expectorated or swallowed. Pharmaceutically compatible
vents; antibacterial agents such as benzyl alcohol or methyl
binding agents, and/or adjuvant materials can be included as
parabens; antioxidants such as ascorbic acid or sodium bisulpart of the composition. The tablets, pills, capsules, troches
fate; chelating agents such as ethylenediaminetetraacetic
55 and the like can contain any of the following ingredients, or
acid; buffers such as acetates, citrates or phosphates and
compounds of a similar nature: a binder such as microcrysagents for the adjustment of tonicity such as sodium chloride
talline cellulose, gum tragacanth or gelatin; an excipient such
or dextrose. pH can be adjusted with acids or bases, such as
as starch or lactose, a disintegrating agent such as alginic acid,
hydrochloric acid or sodium hydroxide. The parenteral prepaPrimogel, or corn starch; a lubricant such as magnesium
ration can be enclosed in ampules, disposable syringes or
60 stearate or Sterotes; a glidant such as colloidal silicon dioxmultiple dose vials made of glass or plastic.
ide; a sweetening agent such as sucrose or saccharin; or a
Pharmaceutical compositions suitable for injectable use
flavoring agent such as peppermint, methyl salicylate, or
include sterile aqueous solutions (where water soluble) or
orange flavoring.
dispersions and sterile powders for the extemporaneous
For administration by inhalation, the compounds are delivpreparation of sterile injectable solutions or dispersion. For 65 ered in the form of an aerosol spray from pressured container
intravenous administration, suitable carriers include physior dispenser which contains a suitable propellant, e.g., a gas
such as carbon dioxide, or a nebulizer.
ological saline, bacteriostatic water, Cremophor EL™
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Systemic administration can also be by transmucosal or
transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated
are used in the formulation. Such penetrants are generally
known in the art, and include, for example, for transmucosal
administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished
through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated
into ointments, salves, gels, or creams as generally known in
the art.
The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as
cocoa butter and other glycerides) or retention enemas for
rectal delivery.
In one embodiment, the active compounds are prepared
with carriers that will protect the compound against rapid
elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery
systems. Biodegradable, biocompatible polymers can be
used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid.
Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be
obtained commercially from Alza Corporation and Nova
Pharmaceuticals, Inc. Liposomal suspensions (including
liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically
acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as
described in U.S. Pat. No. 4,522,811.
It is especially advantageous to formulate oral or parenteral
compositions in dosage unit form for ease of administration
and uniformity of dosage. "Dosage unit form" as used herein
refers to physically discrete units suited as unitary dosages for
the subject to be treated; each unit containing a predetermined
quantity of active compound calculated to produce the
desired therapeutic effect in association with the required
pharmaceutical carrier. The specification for the dosage unit
forms of the invention are dictated by and directly dependent
on the unique characteristics of the active compound and the
particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.
VIII Uses
In one aspect, the invention can be used to prevent, reduce,
or ameliorate disorders associated with apoptosis. Examples
of disorders associated with apoptosis include, but are not
limited to, ischemia-reperfusion injury (e.g., stroke, myocardial infarction), heart failure-( e.g., loss of myocardiocytes );
neurodegeneration disorders-(e.g., Alzheimer's disease,
Parkinson's disease, Huntington's disease and amytrophic
lateral sclerosis); inflanmiation; osteoarthritis; human immunodeficiency virus-(loss ofT lymphocytes); bacterial infection-(apoptosis-inducing virulence proteins are secreted
into the cytosol ofhost cell. e.g., Shigella species, Salmonella
species, Yersinia species and Chlamydia species); allograft
rejection and graft versus host disease; type 1 diabetes; and,
trauma (spinal-cord injury, brain injury).
Other embodiments and used of the invention will be
apparent to those skilled in the art from consideration of the
specification and practice of the invention disclosed herein.
All U.S. patents and other references noted herein for whatever reason are specifically incorporated by reference.
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Methods and Materials
(i) Preparation ofFITC-Labeled, Dephosphorylated Casein
Casein-Dephosphorylated-casein (Sigma, 3 ml of2 mg/ml
stock solution) was used in a dialysis cassette (Pierce) placed
in labeling buffer (0.03 mg/ml FITC, 50 mM sodium borate,
pH 9.3, 40 mM NaCl) and kept for 48 hat 4° C. in the dark
with constant stirring. After labeling, the FITC-dephosphorylated casein (Dcasein-FITC) was further dialyzed against
50 mM Tris-HCl, pH 7.5, and 50 mM NaCl to remove any
residual unlabeled FITC. The Dcasein-FITC conjugate was
recovered from the dialysis cassette and stored at 4° C. in the
dark.
(ii) Expression and Purification ofMBP-Omi and MBP-L56
Proteases-PCR was used to amplify DNA sequences corresponding to Omi/HtrA2 (amino acids 134-458) and L56/
HtrAl (amino acids 140-480). The PCR products were
digested with MfeI and XbaI and cloned in the corresponding
EcoRI and XbaI restriction sites of pMAL-p2X vector (New
England Biolabs). MBP-Omi-(134-458) and MBP-L56(140-480) proteases were expressed in TB! Escherichia coli
(New England Biolabs) and purified on an amylase binding
affinity column as described by the manufacturer (New
England Bio labs). The concentration of purified proteases
was determined using the Bradford assay.
(iii) Expression and Purification of His-Tagged Omi-(134458)
PCR was used to amplify the DNA sequence corresponding to Omi/HtrA2 (Omi-(134-458)). The PCR product was
cloned in-frame in the bacterial expression vector pET-28
(Novagen). For bacterial expression, BL21 (DE3) (Novagen)
bacteria were transformed with pET-Omi-(134-458). Single
colonies were grown overnight in LB medium containing
kanamycin. The overnight culture (1 ml) was used to inoculate I liter of LB medium, and growth was continued at 3 7° C.
until the A 600 was -0.8. At this time, 1 mM mist isopropyl1-thio-~-D-galactopyranoside was added, and the culture was
placed in a shaking incubator overnight at 20° C. Bacteria
were harvested by centrifugation and lysed in a buffer containing 20 mM Tris-HCl, pH 7.5, 500 mM NaCl, 100 µg/ml
lysozyme, and a protease inhibitor mixture (Sigma). The
bacterial suspension was then sonicated, and the soluble fraction was purified using nickel-nitrilotriacetic acid His-Bind
resin (Novagen). The purity of the HisOmi-(134-458) protein
was monitored by SDS-PAGE and Coomassie Blue staining
of the resulting gel.
(iv) Proteolytic Activity ofOmi Using Dcasein-FITC as Substrate
Opaque microtiter plates (corning Glass) were used in
order to minimize background absorbance. A typical assay
included 10 µg of Dcasein-FITC substrate, 2 µg of MBPOmi-(134-458) in assay buffer (20 mMNa 2 HP04 /NaH 2 P04 ,
pH 7.4, 200 mM NaCl, 5% glycerol) in a final volume of 100
µ!. Dcasein-FITC conjugate solution (50 µl of a 0.2 µg/µl
stock solution) was added in each well using a Multidrop 384
multiple dispenser (Lab systems) and incubated in the Wallac
1420 Victor Multilabel counter at 37° C. for 15 min. After
this time, 50 µl of MBP-Omi-(134-458) protease (40 ng/µl)
was added to each well. The fluorescence (535 nm) of the
reactions was recorded every 5 min for a 30-min period.
(v) Combinatorial Library Screening
A Pharma Library Collection from Nanoscale Cominatorial Synthesis Inc., 625 Clyde Ave, Mountain View, Calif.
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94943-2213 was screened for compounds, which may inhibit
the proteolytic activity ofMBP-Omi-(134-458) in an in vitro
assay. Each compound, (from a total of 528 compounds) 10
µM final concentration, was preincubated with 50 µl ofMBPOmi-(134-458) (2 µg) for 15 min at 37° C. After this time,
Dcasein-FITC solution (10 µg) was added, and the change in
fluorescence was read every 5 min during a 30-min period
using a 535-nm bandpass filter. The proteolytic activity of
MBP-Omi-(134-458) was expressed as the percentage inhibition, where 100% refers to the activity in the absence of
inhibitor (Me 2 SO replaced the inhibitor in the assay).
(vi) Activity of Several ucf Analog Compounds Against
MBP-Omi-(134-458)
The assay was performed as described above using
Dcasein-FITC as substrate. 2 µg ofMBP-Omi-(134-458) was
incubated with various concentrations of ucf-101, ucf-102,
ucf-103, or ucf-104 for 15 min. After this time 10 µg of
Dcasein-FITC substrate was added, and the reaction proceeded for an additional 30 min. The activity ofMBP-Omi(134-458) was monitored at 535 nm.
(vii) Determination of IC 50 for ucf-101 and ucf-102.
The IC 50 value for each of the two selected inhibitors was
obtained using His-Omi-(134-458) and the EnzCheck assay
kit (Molecular Probes) that contains BODIPY FL-casein as a
generic substrate. Briefly, 35 µl of His-Omi(134-458) (500
nM) diluted in 20 mat Na 2 HP04 /NaH 2 P04 , pH 7.4, 200 mM
NaCl, 5% glycerol was incubated with 5 µl of various concentrations of the inhibitors (0.1-1000 µM) in 100% Me 2 SO
(final concentration ofMe 2 SO was 10%); 10 µl ofBODIPYFL casein (2.5 µM final concentration) diluted in buffer was
added. The assay was carried out using 384-well microtiter
plates. Fluorescence was monitored continuously for 10 min
at 3 7° C. on a Tecan SpectraFluor Plus microtiter plate reader
(Tecan, Crailsheim, Germany) at an excitation wavelength
485 nm/emission wavelength 530 nm. IC 50 values were calculated using the GraFit 4 program (Erithacus Software,
Middlesex, UK).
(viii) Activity of ucf-101 Against Various Serine Proteases
The amount of the inhibitor giving a 50% (IC 50 ) decrease
of the enzyme activity compared with the control reaction
was estimated for various serine pro-teases. Briefly, 35 µl of
the indicated enzyme diluted in the corresponding buffer was
incubated for 10 min with 5 µl of various concentrations of
inhibitor(0.1-1000 µM) in50% Me 2 50, 50% buffer.After this
time, 10 µl of the corresponding peptidic colorimetric or
fluorogenic substrate diluted in buffer was added. In the case
of the FVIIa/TF assay, a preincubation of both proteins for 10
min at room temperature was performed prior to addition of
the inhibitor to allow complex formation. For this experiment
the following materials were used: canine FXa, rat FXa, and
rabbit FXa (Enzyme Research Laboratories); trypsin from
bovine pancreas and human thrombin (Sigma); human plasmin, human t-PA, human t-PA, and human kallikrein (Calbiochem-Novabiochem); human APC and recombinant
human factor VIIa (American Diagnostica ); and recombinant
tissue factor (Dade Behring). The substrates used are as follows: spectrozyme FXa fluorogenic (American Diagnostica);
kallilkrein fluorogenic substrate; protein C-activated substrate (Calbiochem); Chromozym X, Chromozym Pl, and
Chromozym t-PA (Roche Diagnostics); I-1045, I-1140, and
I-1140 (Bachem).
The amount of each enzyme and its corresponding substrate used in the assay was canine FXa (2 nM), spectrozyme
fXa fluorogenic (20 µM), rat FXa (5 nM), spectrozyme fXa
fluorogenic (25 µM), rabbit FXa (5 nM), spectrozyme FXa
fluorogenic (15 µMr), kallilkrein (5 nM), kallikrein fluorogenic substrate (50 µM), trypsin (2.5 nM), Chromozym X

(150 µM), plasmin(5 nM), I-1045 (100 µM)thrombin( 4nM),
Chromozym PL (150 µM), FVIIa/tissue factor (15 nM/3 nM),
Chromozym t-PA (500 µM), t-PA (100 nM), I-1140 (200
µM), u-PA (3 nM), I-1140 (150 µM), activated protein C (5
nM), and protein C-activated substrate (100 µM) in a final
concentration of 5% Me 2 SO. All enzymatic assays were carried out at room temperature in 384-well microtiter plates
(Nurre). Color development due to the release of p-nitroanilide from the chromogenic substrates was monitored continuously for 20 min at 405 nm on a Tecan SpectraFluor Plus
microtiter plate reader (Tecan). fluorescence from the release
of the coumarin derivative, aminomethylcoumarin, was measured at excitation 360 nm/emission 465 nm on the same
reader. The IC 50 values were calculated using the GraFit 4
program (Erithacus Software).
(ix) Subcellular Localization ofucf-101
HeLa cells were grown on coverslips using F-12 (Ham's)
nutrient mixture (Invitrogen) supplemented with 10% fetal
calf serum (Sigma), 2 mM L-glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin (Invitrogen). Different
concentrations ofucf-101 were added to the cell media, and
after 2 h cells were washed three times with phosphate-buffered saline and fixed with 4% paraformaldehyde. The coverslips were then placed on glass slides using Fluoromount-G
solution (Southern Biochemical Association). The subcellular localization ofucf-101 was monitored using a LSM510
confocal laser-scarming microscope (Zeiss).
(x) ucf-101 Inhibits Omi-Induced Caspase-independentApoptosis in Caspase-9-/-)
Null Fibroblasts-Caspase-9(-/-) cells were transfected
with eitherpEGFP-Nl vector (Clontech) or M-Omi-GFP that
encodes a cytoplasmic form of Omi/HtrA2 (Hegde et al
(2002) J. Biol. Chem. 277, 432-438). Transfected cells were
kept in medium containing different concentrations of ucf101. This medium, including the inhibitor, was replaced every
12 h. After 36 h, cells were stained with propidium iodide and
4',6-diamidino-2-phenylindole as described (Hegde et al
(2002) J. Biol. Chem. 277, 432-438). Normal and apoptotic
GFP-expressing cells were counted using fluorescence
microscopy.
HeLa cells were transfected with mature Omi (aa134-458),
Omi-A VPS-GFP and mature Omi where the first Alanine (A)
was mutated to a Glycine. Omi-GVPS-GFP transfected cells
were treated with increasing concentration of ucf-101. Overexpression of mature Omi-GVPS-GFP can induce apoptosis
only through its ability to function as an active protease
(caspase-independent pathway). ucf-101 inhibited the protease activity and apoptosis.
(xi) Kidney Ischemia/Reperfusion
Kidney ischemia/reperfusion experiments were performed
using Balb/c male mice, 20-25 grams, which were anesthetized with sodiumpentobarbital (65 mg/kg) i.p. and undergo
uninephrectomy of the left kidney followed 24 h later by
ischemia of the right kidney. This is done by placement of a
microaneurysm clamp on the renal artery and vein for 30 min
followed by reperfusion (104). Kidneys were harvested 1, 24,
and 48 h after reperfusion.
In bilateral ischemia experiments, ischemia were performed for 30 mM followed by reperfusion (Kelly, et al.
(1996) J Clin Invest, 97, 1056-63). Kidneys will be harvested
at the same time points as with nephrectomy/unilateral
ischemia. Equal amounts of protein extracts from control and
post-ischemic kidneys will be resolved and analyzed by SDSPAGE. The level ofOmi/HtrA2 protein will be determined by
Western blot analysis using a specific antibody (Hegde, et al.
(2002) J Biol Chem, 277, 432-8; and Faccio, et al. (2000) J.
Biol. Chem., 275, 2581-8).
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(xii) Immunohistochemistry
Kidneys from control or post-ischemic mice were briefly
perfused in situ via the heart with PBS (0.9% NaCl in 10 mM
sodium phosphate buffer, pH 7.4 ), followed by 2% paraformaldehyde, 70 mM lysine, and 10 mM sodium periodate (PLP)
and fixed as (Breton, et al. (1998) J Am Soc Nephrol, 9,
155-66). Kidney slices were immersed in 30% sucrose then
frozen in liquid nitrogen Semi thin (1 mm). Sections were cut
from tissue embedded in LX-112 and treated for 2 minutes
with a mixture of2 g KOH, 5 ml propylene oxide, and 10 ml
methanol to remove the resin. Alternatively, 1 and 5 mm
cryostat sections were used. Sections will be incubated for 10
min in PBS containing 1% BSA to reduce non-specific background staining, followed by a 2-hour incubation at room
temperature with a 20-1 drop of specific antibody. After 3x5min rinses in PBS, sections were incubated for 1 h with goat
anti-rabbit IgG coupled to fluorescein isothiocyanate (Calbiochem-Behring Corp., San Diego, Calif.), and diluted 1:30
for detection of antigenic sites by immunofluorescence
microscopy. Sections were then rinsed 3x5 min in PBS and
mounted in Gelvatol containing 4% n-propyl gallate (Sigma
Chemical Co., St. Louis, Mo.) to retard quenching of the
fluorescence. Photographs of sections were taken on Kodak
TMAX film using a Nikon FXA photomicroscope with epifluorescence. Some sections were also analyzed using the
ABC-peroxidase procedure. After incubation with the primary IgG, a biotinylated goat anti-rabbit IgG (Vector Laboratories, Burlinghame, Calif.) were applied to sections for 1
hour, followed by the ABC reagent (also from Vector Laboratories) for a further 1 hour. Peroxidase was revealed with
diaminobenzidine and H 2 0 2 , and the sections dehydrated in
ethanol and mounted in Permount (Fisher Scientific Co.).
(xiii) Cell Culture
HK-2 cells were grown in DMEM/HamF12 media supplemented with 10% FCS, hydrocortisone (0.4 µg/ml), insulin,
transferring and sodium selenite (all used at a final cone. 5
µg/ml). LLC-PKl cells were grown in DMEM plus 10% FCS
and MDCK in MEM plus 10% FCS.
(xiv) Isolation of Mouse Primary Kidney Proximal Tubular
(MPT) Cells
MPT cells were isolated from collagenase-digested fragments derived from the cortices of kidneys ofC57BL6 mice
as described (Sheridan, et al. (l993)AmJ Physiol, 265, F342d
h"
1(
)
h
l
)
50; an Kras rnn, et a· 1994 Am JP ysio' 266, F21-30 ·
MPT cells were grown in serum-free medium (1: 1 mixture of
Dulbecco's modified Eagle's medium (DMEM) and Ham's
F-12) containing 15 mM Hepes, 5 µg/ml insulin, 50 nM
hydrocortisone, 5 µg/ml apotransferrin, 50 µg/ml penicillin,
and 50 µg/ml streptomycin. The cells were used between the
5th and 10th day after culture.
(xv) Confocal Microscopy
Mouse proximal tubular cells were grown for 6 days on
microscope cover slides. Adherent cells were washed in PBS,
fixed in 4% paraformaldehyde and made permeable using
ice-cold acetone. Non-specific binding was blocked with 2%
BSA in PBS and, subsequently, cells were stained using a
rabbit anti-Omi and a mouse anti-gp330 antibodies at room
temperature for 2 hours. After three washes with PBS, secondary antibodies cy3 conjugated anti-rabbit and Oregongreen conjugated anti-mouse was added for one hour. Finally,
the cover slips were washed and placed on microscope slides
using Fluoromount-G as the mounting solution. Slides were
observed using a LSM510 confocal laser scanning microscope (Zeiss).
(xvi) ATP Depletion ofMPT Cells Using Chemical Anoxia
MPT cells were incubated in dextrose-free DMEM at 37°
C. in a humidified atmosphere containing 5% C0 2 -95% air.

For control monolayers, not subject to ATP depletion, dextrose (10 mM) will be added to the DMEM medium. ATP
depletion of varying severity was induced using 2 mM antimycin (Sigma) or 5 mM 2-deoxyglucose (DOG) (Sigma)
with and without varying concentrations of dextrose. Antimycin alone causes the most severe ATP depletion and
induces cell death by necrosis. DOG alone causes intermediate ATP depletion and induces apoptotic cell death (95). Six
different metabolic conditions were used: 1) antimycin alone,
2) antimycin +0.25 mM dextrose, 3) antimycin+l mM dextrose, 4) DOG alone, 5) DOG+4 mM dextrose, and 6) DOG+
10 mM dextrose.
(xvii) Cisplatin-InducedApoptosis.
MPT cells was plated in serum-free medium [1: 1 mixture
of DMEM and Ham's F-12] (GIBCO) containing 2 µM
glutamine, 50 U/ml penicillin, 50 mg/ml streptomicyn
(GIBCO), 15 mM HEPES, 5 mg/ml transferring, 5 mg/ml
insulin and 50 nM hydrocortisone (Sigma). Medium was
replaced every 2 days and the cells were used 6 to 8 days later.
The MPT cells were incubated with various concentrations
(10, 20, 50, and 100 mM) of cisplatin or vehicle (methylformamide) for 48 hours and analyzed by Flow Cytometry, or
extracts were prepared for Western blot analysis.
(xviii) Induction ofApoptosis onHK-2 Cell Line Using H 2 0 2
HK-2 cells were cultured in DMEM medium containing 2
mM glutamine, 50 U/ml penicillin, 50 µg/ml streptomycin
(GIBCO), 15 mM HEPES, 5 mg/ml apotransferrin, 5 mg/ml
insulin and 50 nM hydrocortisone. Approximately 90% confluent cells were treated with various concentrations ofH 2 0 2
(10, 20, 50, 100 µM) for 18 hours. Whole cell extracts were
prepared and analyzed by Western blot analysis using Omi/
HtrA2 antibodies.
(xix) Use of siRNAs to Suppress Omi/HtrA2 Expression in
Proximal Tubular Cells.
The pSuppressor2 vector available from Imgenex (San
Diego, Calif., Paul, et al. (2002) Nat Biotechnol, 20, 505-8)
was used to stably express the small interfering RNA (siRNA)
that is homologous to Omi/HtrA2 mRNA sequence.
A double stranded (ds) oligo with the following sequence was
used:
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This double stranded oligo encodes 19 base pairs representing sequence 51-70 nucleotides downstream of the initiation of translation of Omi/HtrA2. The sense and antisense
sequence is separated by a stem loop of 6 nucleotides that
encodes the Sea I restriction site used for easy identification
of the insert. The double stranded oligo was cloned into the
corresponding sites of the pSupressor2 vector and bacterial
clones was screened by isolating plasmid DNA followed by
restriction digest with Sea I restriction enzyme. Positive
clones will have their plasmid DNA sequenced as described
by Faccio, et al. ((2000) J. Biol. Chem., 275, 2581-8). The
pSuppresor/Omi clone was used to transfect HK-2 cells. The
vector has the NeoR gene and permanent cell lines can be
made using G418 (Invitrogen) in the culture medium. The
effectiveness of this siRNA to suppress expression of the
Omi/HtrA2 will be monitored by Western blot analysis using
total cell extracts and anti-Omi antibodies. As a control, cell
lines were made using the pSuppressor2 vector alone.
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(xx) Cell Viability Assay
The viability of cells was monitored using the MTT assay
(Buttke, et al. (1993) J Immunol Methods, 157, 233-40; and
Mossman, (1983) Environ Health Perspect, 53, 155-61 ). The
assay is based on the ability of the mitochondria of viable
cells to cleave the tetrazolium rings of the pale yellow MTT
dye to form dark blue formazan crystals. The amount of
formazan product produced is directly proportional to the
number of viable cells present in the culture well. After
removal of the medium, MTT (1 µg/ml) is added to each well
and incubated at 37° C. for 4 hours. The formazan crystals
formed by viable cells are then dissolved by adding 10%
SDS/0.01 N HCl to each well and incubating overnight. The
absorbance of aliquots from each well will be read by 1420
Multilabel counter Victor2 (Wallac) plate reader with a test
wavelength of 570 nm and a reference wavelength of 650 nm.
Percent viability will be expressed as the absorbance of ATPdepleted cells with the ucf-101 inhibitor/absorbance of ATPdepleted cells without the inhibitor, where DMSO is added
instead.
(xxi) Transfection of Mammalian Cells
60% confluent cells were transfected using the Lipofectamine Plus Reagent according to the instructions provided by the manufacturer (Life Technologies).
(xxi) Quantitative Real-Time PCR Analysis of Omi/HtrA2
mRNA.
Total RNA was isolated from MPT cells using the QIAgen
RNeasy kit following manufacturer's instructions. 2 µg of
total RNA was transcribed into cDNA using the Omniscript
reverse transcriptase (QIAgen). Real-Time PCR was performed with AmpliTaq Gold polymerase in a iCycler realtime PCR thermocycler (BioRad) and the Sy Br Green detection protocol as per the manufacturer's instructions. Briefly,
12 ng of total cDNA, 50 nM of each primer and lx SyBr
Green mix was used in a total volume of 25 µ!. The primer
sequences
for
murine
Omi/HtrA2
are:
Sense
5'-GCGGGGCGGGGTGCAAAC-3' (SEQ ID NO: 4) and
antisense 5'-GACAGCCAGCACCGTGG-3' (SEQ ID NO:
5). Murine b-actin primers: sense 5'-TTCGTTGCCGGTCCACA-3' (SEQ ID NO: 6) and antisense 5'-ACCAGCGCAGCGATATCG-3' (SEQ ID NO: 7). Samples were read in
triplicate and normalized for expression of ~-actin RNA.
(xxii) Western Blot Analysis
For Western blot analysis, cells were harvested 24 hours
after transfection, washed and lysed using a Triton X-100
based buffer (1% Triton X-100, 10% Glycerol, 150 mM
NaCl, 20 mM Tris-HCl pH 7.5, 2 mM EDTA) containing a
protease inhibitors cocktail (Roche). Approximately 30 µg of
the whole cell extracts were re-suspended in SDS-sample
buffer and boiled for 3 minutes. The samples were resolved by
SDS-PAGE and electro-transferred onto PVDF membranes
(Pall Corporation) using a Semi-Dry Transfer Blot (Bio-Rad).
Non-specific binding was blocked using 2% nonfat dry milk
in TBST to saturate the membrane. The blot was then incubated with an anti-GFP monoclonal antibody (Santa Cruz
Biotechnology), 1:700 dilution followed by a secondary
horseradish peroxidase-conjugated goat anti-mouse antibody
(Jackson ImmunoResearch), 1: 15000 dilution, and visualized by chemiluminescence (ECL) using a SuperSignal West
Pico substrate (Pierce).
(xxiii) Flow Cytometry
Cells were grown on 6 well plates using appropriate media.
60% confluent cells were transfected with various constructs
using Lipofectamine Plus Reagent according to the instructions provided by the manufacturer (Life Technologies). The
transfected cells were detached 48 hours later, washed twice
with ice-cold PBS, resuspended in 1x binding buffer (BD

Bioscience) and stained with PE-conjugated annexin V
according to BD Bioscience protocol. Analysis of GFP and
annexin V positive cells will be performed on a FACS Vantage
Flow Cytometer (Becton Dickinson).
5
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Activity of Omi Protease Against Dcasein-FITC
This example demonstrates the activity of Omi protease
against Dcasein-FITC. As no physiological substrates for
Omi protease are known, ~-casein was used as a generic
substrate in in vitro assays to monitor the protease activity of
Omi. For high throughput screening, a new assay was developed that uses a mixture of a-casein, ~-casein, and dephosphorylated casein (Dcasein) coupled to FITC, as a substrate,
The use of Dcasein-FITC increases the fluorescence during
the reaction with less fluctuation and lower background (data
not shown). A typical assay uses 10 µg of Dcasein-FITC and
2 µg MBP-Omi-(134-458) in 100 µl of reaction buffer (20
mM sodium phosphate buffer, pH 7 .5, 200 mMNaCl, and 5%
glycerol) at 37° C. for 30 min.
The results show that there was a rapid increase in fluorescence for the first 20 min followed by a slower increase forthe
remaining 10 min of the assay. Various concentrations of
substrate, Dcasein-FITC, as well as MBP-Omi-(134-458)
were used for kinetic studies.
Example 3
Combinatorial Library Screening
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By using an in vitro high throughput assay system, a combinatorial library of synthetic compounds (Nanosyn) was
screened. This collection represented compounds that had
commonly accepted pharmaceutical hit structures with possible pharmacological properties. The assay was performed
in multiple 96-well plates. The inhibition activity of each
compound was expressed as the percentage of relative fluorescence change (decrease) compared with the control (no
compound). The final concentration of each compound tested
was 10 µM. Fifty two compounds showed more than a 20%
inhibition of MBP-Omi-(134-458) activity in the initial
screening, but only one compound (ucf-101) showed greater
than a 50% inhibition at the concentration tested after two
rounds of screening and selection (Table III).
TABLE III

55

60

65

Screening for inhibitors oftbe proteolytic activity ofOmi
A combinatorial library of 528 selected compounds was used in a
high tbroughout screening for potential inhibitors oftbe proteolytic
activity ofOmi. Several compmmds had weak activity against Omi,
but after two rounds of selection only one chemical showed
substantial and reproducible inhibition against Omi in the assay used.
% inhibition

1st screening

0
1-19
20-39
40-59

468
52
2

Total

528

2 screening

26
47

75
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Example 4

Example 6

Inhibition of the Proteolytic Activity of
MBP-Omi-(134-458) Using ucf-101 and Various
Analogs

Comparison of the Proteolytic Activities of His-Omi
(134-458) and His-L56-(156-480)

Several analogs ofucf-101 were obtained, and the chemical structures are shown in FIGS.1-4. The activity of these ucf
analogs was tested using MBP-Omi-(134-458) in the same in
vitro assay system. FIG. 7 shows the inhibition ofMBP-Omi(134-458) by ucf-101 and several other ucf analogs. The
assay was performed with 10 µg ofDcasein-FITC incubated
with 2 µg ofMBP-Omi-(134-458) in the presence of various
concentrations of ucf-101 and three analogs, ucf-102, ucf103, and ucf-104. •, ucf-101; .._, ucf-104; e, ucf-103; +,
ucf-102. All three analogs inhibited the proteolytic activity of
MBP-Omi-(134-458) but to a lesser extent than ucf-101. ucf104 (20 µM) inhibited 58% MBP-Omi-(134-458) activity,
whereas the same concentration of ucf-101 inhibited more
than 78% MBP-Omi-(134-458) activity. When MBP-Omi(134-458) was preincubated with various concentrations of
ucf-101, -102, -103, and -104 at 37° C for longer periods (40
mill or 1 h) inhibition was reduced, indicating the inhibitors
did not irreversibly bind the enzyme (results not shown).
MBP-Omi-(134-458) was also incubated with various
amounts ofDcasein-FITC in the presence of 10 µM ucf-101.
The rate of the reaction decreased by 50% when the concentration of the substrate was doubled and even reached the rate
of the control reaction at higher concentrations of DcaseinFITC (results not shown). These results suggest ucf-101 is a
competitive inhibitor of Omi protease.
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15

20

Proteins-OmiHtrA2 and L56/HtrA1 are members of the
same family of mammalian serine proteases with extensive
homology in their catalytic domains (Faceio et al. (2000) J.
Biol. Chem. 275, 2581-2588). Bacterially made His-Omi(134-458) and His-L56-(140-480) was used to investigate
whether ucf-101 was able to inhibit the activity ofHis-L56(140-480) in a similar manner. FIG. 9 shows the inhibition of
the proteolytic activity of MBP-Omi-(134-458) and MBPL56-(140-480) by ucf-101. The assay was performed with 10
µg ofFITC-Dcasein and 2 µg ofMBP-Omi-(134-458) (MBPOmi) or MBP-L56-(140-480) (MBP-L56) in the presence of
various concentrations ofucf-101. The increase in fluorescence for the initial 20 min was used for comparing the
activities of MBP-Omi-(134-458) or MBP-L56-(140480). +, MBP-Omi; • MBP-L56.
FIG. 9 shows ucf-101 is an effective inhibitorof the activity
of His-L56-(140-480) but to a lesser extent than His-Omi(134-458).
Example 7

25

IC 50 ofucf-101 Against Various Serine Proteases

30

The enzymatic activity of His-Omi and the determination
of the IC 50 for ucf-101 and ucf-102 were performed as
described in Example 1 (vii). These values are shown in Table
IV. ucf-101 hadanIC 50 of9.5 µM, and ucf-102 hadanIC 50 of
45.9 µM.

Example 5
TABLE IV

35

Assay ofHis-Omi-(134-458) Activity Using
Unlabeled ~-Casein and SDS PAGE Analysis
The inhibitory effect ofucf-101 on the activity ofHis-Omi(134-458) was monitored by incubating inhibitor and enzyme
together for 10 min at room temperature prior to the addition
of ~-casein as a generic substrate. An in vitro assay of the
proteolytic activity ofHis-Omi-(134-458) in the presence of
different concentrations of ucf-101 was performed, and the
results shown in FIG. 8. The assay was performed at 37° C.,
and after the indicated time points the reactions were resolved
on SDS-PAGE and the gel stained with Coomassie Blue. Omi
(200 ng) was incubated with 5 µg of~-casein substrate in a 20
µl reaction volume for 30 min at 37° C. The ucf-101 compound was preincubated with His-Omi-(134-458) (His-Omi)
protease for 10 min at room temperature prior to the addition
of ~-casein substrate. (Lane 1, ~-casein control; lane 2, HisOmi+~-casein, digested for 15 min; lane 3, His-Omi+~
casein, digested for 30 min; lane 4, His-Omi+lOO µM ucf101+~-casein; lane 5, His-Omi+80 µM ucf-101+~-casein;
lane 6, His-Omi+50 µM ucf-101 +~-casein; lane 7, His-Omi+
30 µM ucf-101+~-casein; lane 8, His-Omi+20 µM ucf-101+
~-casein; lane 9, His-Omi+lO µM ucf-101+~-casein; and lane
10, prestained molecular weight marker.)
FIG. 8 shows that bacterially made His-Omi-(134-458)
had substantial activity against ~-casein, and after 30 min
total degradation of the substrate occurred. ucf-101 inhibited
His-Omi-(134-458) activity in a concentration-dependent
manner (lanes 4-9) when assayed for 30 min with 200 ng of
His-Omi-(134-458) and 5 µg of ~-casein. ucf-101 (80 µM)
was able to inhibit completely the activity of 200 ng of HisOmi-(134-458) (lane 5).

IC, 0 ofucf-101 and ucf-102 inhibitors on His-Omi

1C 50 in µM

Inhibitors
40

ucf-101
ucf-102

9.5
45.9

The value is the average from three independent experiments.

45

The specificity of ucf-101 was determined using several
unrelated serine proteases. Their susceptibility to inhibition
by ucf-101 was tested. The IC 50 values for ucf-101 inhibitor
from these experiments are shown in Table IV. These results
suggest ucf-101 has very high specificity for the Omi protease.

50

TABLE IV
IC 50 values ofucf-101 on various protease
Protease
55

Canine-Fxa
Rat-Fxa
Rabbit-Fxa

60

Hu-kallikrein
Bovine-trypsin
Hu-plasmin

65

Hu-thrombin

IC 50 inµM
430
360
410
>500
260
300
200
250
>500
>500
>500
400
>500
>500
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similar to Smac/DIABLO, another mitochondrial protein that
TABLE IV-continued
also binds to XIAP (Du et al. (2000) Cell 102, 33-42; and
IC 5a values ofucf-101 on various protease
Verhagen et al., (2000) Cell I 02, 43-53 ). This interaction with
XIAP is mediated via an AVPS motif that is exposed at the
Protease
IC 50 inµM
5 amino terminus of mature Omi protein after processing (SuHu-rec.-FVIIa
>500
zuki et al. Supra, Hegde et al. Supra).
>500
Omi/HtrA2 is also able to induce apoptosis in a caspaseHu-t-PA
390
independent manner that exclusively relies on its ability to
390
Hu-u-PA
500
function as a protease (Suzuki et al. (2001) Mal. Cell. 8,
500
10 613-621; Hegde et al. Supra; Martins et al. (2002) J. Biol.
Hu-APC
500
Chem. 277, 439-444; Verhagen et al. Supra; and van Loo et al.
500
(2002) Cell Death Differ. 9, 20-26). This caspase-independent
The two IC 50 values are derived from two independent experiments.
pathway is not well understood; its contribution to overall cell
The two IC 50 values are derived from two independent experiments.
death is not known, and the role of Omi as a protease in this
15 pathway is not clear. Because the caspase-independent pathway relies on the ability of Omi/HtrA2 to function as a proExample 8
tease, it suggests that proteolytic cleavage of specific proteins
is involved. This cleavage might inactivate and remove apoIntracellular Localization of ucf-101
ptotic inhibitors, or it may activate precursor proteins whose
20 function might be necessary for caspase-independent cell
To investigate the potential use of ucf-101 inhibitor in in
death.
vivo experiments, the ability of the inhibitor to enter mamIn order to investigate the contribution of the proteolytic
malian cells was tested. ucf-101 has natural fluorescence at
activity of Omi to its overall pro-apoptotic function, specific
543 nm that was used to detect the presence of the compound.
inhibitor(s) of its activity were screened. One such specific
HeLa cells were treated with different concentrations ofucf- 25 inhibitor was identified and called ucf-101. This heterocycic
101 and observed by confocal microscopy. Intense red fluocompound was able to inhibit the proteolytic activity of Omi
rescence, due to the presence ofucf-101, was observed in the
in vitro in a very specific and reversible manner. The specicytoplasm of the treated cells.
ficity ofucf-101 was tested against a panel of several unreThe cytoplasmic localization of ucf-101 was examined
lated serine proteases, and no significant activity was
when subconfluent HeLa cells were treated with 50 (A), 40 30 detected. When L56/HtrA1 was used in the same assay, ucf(B), and 20 µM (C) ucf-101 and were observed using a con101 showed specific inhibition against this protease. L56/
focal microscope. A-C show cytoplasmic red staining due to
HtrAl belongs to the same family of proteases as Omi, and
the presence of ucf-101, indicating cells are permeable to this
they both share extensive homology throughout their respective catalytic domains (Faceio et al. (2000) J. Biol. Chem. 27 5,
chemical. No staining was seen when Me 2 SO alone was used.
35 2581-2588). The normal functionofL56/HtrA2 is not known,
D (results not shown)
and unlike Omi that localizes to mitochondria, L56 is secreted
Example 9
(Ru et al. (1998) J. Biol. Chem. 273, 34406-34412). The
natural fluorescence ofucf-101 was used to monitor its ability
ucf-101 Can Inhibit Omi-Induced
to enter mammalian cells. This property is necessary for
Caspase-Independent Apoptosis
40 ucf-101 to be useful for in vivo experiments designed to test
inhibition of Omi that is intracellular.
The inhibition of Omi-induced caspase independent cell
To test the ability of ucf-101 to inhibit the proteolytic
death by ucf-101 was examined. Mouse embryo caspaseactivity of Omi in vivo, an assay was used where transient
9 (-/-/-)null fibroblasts (Hakem et al. (1998) Cell 94; 339overexpression of a cytoplasmic form of Omi induces
352) were transiently transfected with pEGFP-Nl (control) 45 caspase-independent cell death (Hedge et al, supra). The cells
or Omi-GFP (Hegde et al, Supra). The transfected cells were
used in this assay were caspase-9 (-/-)null mouse embryonic
kept in medium containing different concentrations of ucffibroblasts (Hakem et al. supra)) in which over-expression of
101. The percentage of apoptotic cells in the transfected
a cytoplasmic form ofOmi can induce the caspase-indepenpopulation was determined after 36 has described by Hakem
dent pathway of apoptosis. This form of cell death caused by
et al. (1998), Supra.
50 Omi relies entirely on its ability to function as a protease.
Cytoplasmic expression of M-Omi-GFP induced apoptoTherefore, ifucf-101 blocks the activity ofOmi, it will intersis in -70% of the transfected cells. When cells were treated
fere with apoptosis of the caspase-9 (-/-)mouse embryonic
with increasing concentrations ofucf-101, it was found that
fibroblasts. When these fibroblasts were transfected with the
increasing the concentration of inhibitor up to 10 µM graduvector encoding the cytoplasmic Omi and treated with ucfally reduced Omi-induced apoptosis up to 40%. ucf-101 had 55 101, apoptosis was dramatically reduced.
no effect on the control (vector alone) transfected cells. When
Example 10
the concentration of the ucf-101 increased to 25 µM, the
anti-apoptotic activity of the inhibitor was compromised due
Omi/HtrA2 is Predominantly Expressed in the
to a cytotoxic side effect that caused apoptosis both in the
Proximal Kidney Tubules
M-Omi-GFP, as well as control transfected cells (FIG. 10). 60
Collectively, these results demonstrate that Omi/HtrA2 is a
To determine the expression profile of Omi/HtrA2 in kidmitochondrial serine protease that is released to the cytoney cells, immunocytochemical staining for Omi/HtrA2 was
plasm upon induction of apoptosis. In the cytoplasm, Omi
performed as described (Faccio et al. (2000). J. Biol. Chem.,
binds to XIAP and relieves its inhibition of caspase-9 (Suzuki
eta!. (2001)Mol. Cell. 8, 613-621; Hegde et al. (2002)J. Biol. 65 275, 2581-8 and Park, et al (2002) J Biol Chem, 277, 2040Chem. 277, 432-438; and Verhagen et al., (2002) J. Biol.
9)). Human kidney sections were obtained from Biochain
Chem. 277, 445-454). In this respect, Omi acts in a manner
Institute Inc. (Hayward, Calif.) and mouse sections were pre-
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pared as previously described (Faccio et al (2000 Supra).
Omi/HtrA2 antiserum was raised against bacterially made
His-tagged Omi/HtrA2 protein (residues 134-458) and affinity purified (Hegde, et al (2002) Supra). Proximal tubules
were identified by apical staining with anti-gp330 (also
known as megalin) (green) (Kerjaschki, et al (1982) PNAS,
79, 5557-81). Omi/HtrA2 protein expression was indicated
by red staining; when both images are merged there was
extensive co-localization of gp330 and Omi/HtrA2. Both
human and mouse kidney sections showed the same expression profile.

HtrA2 (red) (1 ). The same MPT cells stained with anti-gp330
antibodies (green) (2) and Nomarsky images of the MPT cells
were also produced. The results show that Omi/HtrA2 protein
and distinct punctate perinuclear staining in normal MPT
cells and co-localizes with mitochondrial staining. After
induction of apoptosis MPT cells show more intense Omi/
HtrA2 staining that is more diffuse and extends throughout
the cell.

5

10

The Protein Level of Omi/HtrA2 Increases in MPT
Cells Induced with Various Apoptotic Stimuli

Example 11
Expression of Omi/HtrA2 is Upregulated After
Ischemia/Reperfusion
To show that Omi/Htra2 was upregulated after ischemia/
reperfusion, Balb/c male mice underwent uninephrectomy of
the left kidney and, 24 hours later, ischemia was induced on
the right kidney for 30 min followed by reperfusion (Park, et
al. (2002) J Biol. Chem., 277, 2040-9). Kidneys were harvested 90 min and 24 hours after reperfusion and processed as
described in Example 1 (xi). Sections of mouse kidneys
showed a substantial increase in the intensity of Omi/HtrA2
staining 90 min and 24 hours after ischemia/reperfusion as
compared with sham operated kidneys withAnti-Omi having
a red fluorescence and anti-gp330 having a green fluorescence (data not shown).
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Example 12
Expression of Omi/HtrA2 Protein in Proximal
Tubule (MPT) Cells
35

To investigate the expression of Omi/HtrA2 protein in
proximal tubule (MPT) cells, MPT cells were isolated from
the kidneys of 4-5 week old mice as described in the Example
1. Confocal microscope images of two representative populations of MPT cells were stained with anti-Omi (red) and
anti-gp330 (green). Mouse proximal tubular cells were grown
for 6 days on microscope cover glass. Adherent cells were
stained using a rabbit anti-Omi and a mouse anti-gp330 at
room temperature for 2 hours. Secondary antibodies used
were: cy3 conjugated anti-rabbit and Oregon-green conjugated anti-mouse. Images were obtained using a LSM510
confocal laser scanning microscope (Zeiss). MPT cells were
stained with anti-Omi/HtrA2 (Al and Bl). The same MPT
cells were stained with anti-gp330 antibodies (green) (A2 and
B2). Merged images of 1 and 2 (A3 and B3). Nomarsky
images (A4 and B4). The results show that all MPT cells
identified by staining with anti-gp330 also stained positive
with anti-Omi/HtrA2 (data not shown).
Example 13

To investigate the protein level of Omi/HtrA2, MPT cells
were isolated and exposed to different concentrations of cisplatin for 48 hours, or they were treated with 2 µM antimycin
for different time periods. Approximately 5 µg protein of total
cell extract was resolved by SDS-PAGE, transferred to a
PVDF membrane and probed using the anti-Omi antibodies
as described in Example 1.
Western blot analysis showed up-regulation of Omi/HtrA2
protein following inductionofapoptosis (See FIG. lla ). Both
cisplatin and antimycin treatment induced expression ofOmi/
HtrA2 protein in MPT cells.
A Western blot analysis of Omi/HtrA2 protein in HK-2
(human proximal tubular epithelial cell line) cells after induction of apoptosis using the indicated concentrations ofH 2 0 2
for 18 hours is shown in FIG. llb. The results show that the
basal protein level ofOmi/HtrA2 is higher in HK-2 cells than
in primary MPT cells. In the HK-2 cell line, there is also
substantial increase in the level of the Omi/HtrA2 protein
after induction of apoptosis with H 2 0 2 .
Example 15
Ucf-101 Protects MPT Cells from Cisplatin-Induced
Apoptosis
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Subcellular Localization of Omi/HtrA2 in Normal
and Apoptotic MPT Cells
The subcellular localization of Omi/HtrA2 in normal and
apoptotic MPT cells was investigated by as described in
Example 1. Confocal microscope images of normal or apoptotic MPT cells stained with anti-Omi (red) and MitoTracker
(green) (data not shown). Apoptosis was induced using 2 µM
Antimycin for 1 hour. Omi antibody staining was done as
described in Example 1. 50 nM of MitoTracker dye was
added for 20 minutes. MPT cells stained with anti-Omi/

Example 14
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This example describes the protective effects of an inhibitorofapoptosis, Ucf-101 oncisplatin-induced apoptosis. Cisplatin used at low doses can also induce apoptosis in RTECs
whereas high doses induce necrosis (Lieberthal, et al. (1996)
Am J Physiol, 270, F700-8; and Lau, et al. (1999) Kidney Int,
56, 1295-8). Early animal studies have shown apoptosis to
occur in rat kidney cortexes 12 hours after ischemia/reperfusion (Schumer, et al. (1992) Am J Pathol, 140, 831-8). More
studies have described apoptosis to occur in ischemia/reperfusion injury to the kidney (Nakajima, et al. (1996) Am J
Physiol, 271, F846-53; Yin, et al. (1997) J Biol Chem, 272,
19943-50; Nogae, et al. (1998) J Am Soc Nephrol, 9, 620-31;
and Raafat, et al. (1997) Shock, 8, 186-92). Ucf-101 was
isolated for its ability to inhibit the proteolytic activity of
Omi/HtrA2 in vitro (Cilenti, et al. (2003) J Biol Chem, 278,
11489-94).
The ability ofucf-101 to passively enter mammalian cells
makes it possible to be used for in vivo studies. It was hypothesized that ifOmi/HtrA2 through its proteolytic activity plays
a role in tubular cell death following renal injury, ucf-101
inhibitor will have a protective anti-apoptotic function in the
same system. Previous studies have shown that treatment of
MPT cells with cisplatin caused increased expression of p53,
and this induction of p53 was necessary and essential for
cisplatin-induced apoptosis (Cummings, et al. (2002) J Pharmacol Exp Ther, 302, 8-17; and Xiao, et al. (2003) J Toxicol
Environ Health A, 66, 469-79). Furthermore, a recent report
showed that Omi/HtrA2 expression is directly regulated by
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p53 at least in HeLa cells (Jin, et al. (2003) Genes Dev, 17,
359-67). It was therefore hypothesized that Omi/HtrA2 was
involved in the cisplatin-induced apoptosis as a downstream
effector of p53 and ucf-101 was tested as an inhibitor of in
cisplatin-induced apoptosis.
FIG. 12 shows that ucf-101 blocks cisplatin-induced apoptosis in MPT cells. MPT cells were treated with either 20 µM
or 50 µM ucf-101 for 20 minutes. After this time, apoptosis
was induced with different concentrations of cisplatin for 6
hours. Cells were detached, washed with PBS and stained
withannexin Vaccordingto BD Biosciences protocol.Analysis of annexin V positive cells was performed on a FACS
Vantage Flow Cytometer (Becton Dickinson). Results shown
are the average values from three independent experiments.
The data shows that ucf 101 reduces apoptosis in a dosedependent manner in cisplatin induced apoptotic cells.
Collectively, the data shows that Omi/HtrA2 is expressed
in the kidney proximal tubules, an area highly susceptible to
injury and cell death. Furthermore, the protein level of Omi/
HtrA2 dramatically increased after kidney ischemia/reperfusion in MPT cells treated with antimycin or cisplatin as well
as in HK-2 cells treated with H 2 0 2 . Finally, ucf-101, a specific inhibitor of the proteolytic activity ofOmi/HtrA2, protects MPT cells from cisplatin-induced apoptosis. These
results suggest that Omi/HtrA2 plays an important role in
injury/apoptosis that occurs in proximal tubule cells following ischemic or chemical insult.

protein (GFP). After transfection into mammalian cells, their
localization, processing and ability to induce apoptosis was
monitored.
FIG.14 shows the expression and processing of the various
GFP-fusion proteins. Equal amounts of whole-cell lysates
obtained 24 hours post-transfection were subjected to SDSPAGE followed by immunoblotting using anti-GFP antibodies. Lanes 1-7, cell lysates prepared from HeLa cells transfected with the corresponding construct: Omi-GFP, Omi-S/
A-GFP, Omi-L56-GFP, Omi-L56-S/A-GFP, Omi-li.7-GFP,
Omi-li.3-GFP, and D-Omi-GFP
FIG. 15 shows the results from an apoptotic assay of various GFP-fusion proteins. 293T cells were transfected using
the same constructs shown in FIG. 13. 48 hours later, transfected cells were detached and stained with PE-conjugated
annexin V. The percentage of GFP positive cells that were also
annexin V positive is shown. The number represents the average of four independent experiments.
This data shows that D-Omi, due to its inability to function
as a protease, is not processed to the mature form of the
protein. This causes the amino terminal part (aa 1-133) that is
usually removed in the mature Omi/HtrA2 protein to remain
attached on D-Omi. As a result, D-Omi is unable to induce
apoptosis in a caspase-dependent manner since it can not
expose the AVPS internal sequence motif necessary for binding to the inhibitor of apoptosis proteins (IAPs ). Furthermore,
since it is an inactive protease, it cannot induce apoptosis in a
caspase-independent pathway. The results showed that
D-Omi still retains some residual activity and it is able to
induce apoptosis in 15% oftransfected 293T cells, which is
approximately half the apoptotic potential of mature Omi/
HtrA2. The function ofD-Omi is not known; it could act as a
dominant negative, blocking the activity of Omi/HtrA2, or it
could induce apoptosis in a new, independent mechanism.

Example 16
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The Function ofD-Omi
This example investigates the roles of D-Omi, a kidneyspecific, alternatively spliced form of Omi/HtrA2. Omi/
HtrA2 is expressed ubiquitously but recently an alternatively
spliced form (D-Omi) has been isolated by this group, and is
found predominantly in the kidney and to a lesser extent in the
colon and thyroid (Faccio, et al. (2000) Genomics, 68, 343-7).
D-Omi lacks the amino acid sequence encoded by exons 3
and 7 that affects both its catalytic domain as well as the PDZ
domain. The function of D-Omi is not known. Its restricted
tissue-specific expression might suggest a specific role in the
organs where it is found.
To investigate the function of exon 3 that encodes part of
the catalytic domain as well as exon 7 that encodes part of the
PDZ domain, a number of chimeric proteins were made. A
schematic diagram of these proteins is shown in FIG. 13. This
list contains Omi/HtrA2 as well as D-Omi/HtrA2, Omi-li.3
that lacks only the sequence encoded by exon 3 and Omi-li.7
that lacks the sequence encoded by exon 7. Furthermore,
several other constructs were made where the catalytic activity ofOmi/HtrA2 was destroyed by an S/A substitution and an
Omi/HtrA2 construct where both the catalytic and PDZ
domains have been replaced with the corresponding domains
ofL56/HtrA2. For example, in Omi-SA, the Ser 306 (s) was
replaced withAla (A); Omi-L56 chimera is a construct where
the N-terminus of Omi-HtrA2 including the AVPS motif was
fused to L56 protein form the amino acid 156-480. Omi-L56S/A is a mutated form ofomi-L56, where the Ser 328 has been
mutated to Ala. All of these constructs were cloned into
EGFP-Nl vector. the conserved amino-terminal mitochondria targeting sequence (MTS) is shown, this is followed by
the catalytic domain (which includes the AVPS motif), the
catalyticadomainiffollowedbythePDZdomain.Allofthese
proteins were expressed as fusions with the green fluorescent
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Example 17
Kidney-Specific Substrates for Omi/HtrA2 Protease
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This example describes the identification of substrates for
Omi/HtrA2 protease. Omi/HtrA2 is an active serine protease.
This activity is necessary for processing the precursor protein
to its mature form. This processing exposes an internal AVPS
motif at the amino terminus which is used to bind the inhibitor
of apoptosis proteins (IAP) and induce caspase-dependent
cell death. Furthermore, Omi/HtrA2 can induce apoptosis in
a caspase-independent manner that relies entirely on its ability to function as a serine protease in the cytoplasm of cells.
This observation suggests that the presence of specific substrates for Omi/HtrA2 whose destruction and removal is part
of the caspase-independent apoptotic process. Alternatively,
Omi/HtrA2 might activate a precursor pro-apoptotic protein
through limited proteolytic cleavage.
In order to identify substrates for Omi/HtrA2, the latest
technology in proteomics was used. Human kidney extracts
obtained from BioChain Institute, Inc. (Hayward, Calif.).
These extracts were already fractionated into: (a) kidney
membrane associated proteins and (b) kidney cytoplasmic
proteins. About 200 mg of extract was incubated in the presence of bacterially made His-Omi-134-458. As controls, no
enzyme was added nor was the ucf-101 inhibitor used. After
30 min of incubation at 37° C., the reaction was stopped with
an equal amount of SDS-PAGE buffer. Proteins were analyzed by 2-dimensional gel electrophoresis. This service was
done in Kendrick's lab (Madison, Wis.). This lab specializes
in 2D PAGE and provides a service for academia (http://
www.kendricklabs.com/). When the images of the 2D-gels
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were compared, two polypeptides (32 kD and 291 W) in the
human kidney cytoplasmic fraction were specifically cleaved
by His-Omi (results not shown). This cleavage was prevented
by the specific inhibitor ucf-101. It was also not seen when the
enzyme was left out of the reaction. No proteins were cleaved
in the membrane bound fractions. After scaling-up the reaction, the two polypeptide spots were excised and sent to the
Protein Chemistry Core Facility, Howard Hughes Medical
Institute/Columbia University for mass spectrometry
sequencing.
There, the proteins were identified as 14-3-3 protein and
annexin V. 14-3-3 proteins are small acidic proteins with
molecular mass ranging from 27 to 32 kDa with no detectable
catalytic domain or function (Aitken, et al. (1995) Biochem
Soc Trans, 23, 605-11; Dubois, et al. (1997) J Protein Chem,
16, 513-22; Muslin, et al. (2000) Cell Signal, 12, 703-9;
Shaw, (2000), Curr Biol, 10, R400; and Skoulakis, et al.
(1998) Mal Neurobiol, 16, 269-84. 1998).
There are seven identified 14-3-3 isoforms in mammals
and these are highly conserved through evolution from the
yeast to mammals. 14-3-3 proteins are phosphoserine-binding proteins involved in cellular proliferation, checkpoint
control and apoptosis (Aitken, et al. (1995) supra). The mode
ofaction of14-3-3 proteins is not due to any intrinsic activity.
Instead, it relies entirely on the ability of 14-3-3 proteins to
bind specific targets and modify their activity. For instance,
14-3-3 binding to BAD competes with Bcl2 binding, relieving Bcl2 for its antiapoptotic function (Datta, et al. (2000)
Mal Cell, 6, 41-51). 14-3-3 proteins canalsomodifythetarget
protein localization (Muslin, et al. (2000) Cell Signal, 12,
703-9), bridge two proteins together (Luo, et al. (1996)
Nature, 383, 181-5), alter the catalytic activity of the target
protein, or they can protect the target protein from modifications such as dephosphorylation (Chiang, et al. (2001) Blood,
97, 1289-97). Approximately 70 target polypeptides for
14-3-3 proteins have been identified so far (Tzivion, et al.

(2000) J Biol Chem, 275, 29772-8). If 14-3-3 proteins are
indeed physiological substrates for Omi/HtrA2, it will help to
explain how Omi/HtrA2 causes caspase-independent cell
death. It has been reported that when the 14-3-35 protein (one
of the seven 14-3-3 isoforms) was disrupted in a human
colorectal cancer cell line, cells arrested in the G2 phase and
ultimately perished by non-apoptotic cell death (Chan, et al.
(1999) Nature, 401, 616-20).
Annexin V is a vascular anticoagulant protein that is normally present on the cytosolic site of the plasma membrane
(Tait, et al. (1988) Biochemistry, 27, 6268-76; and Reutelingsperger, et al. (1988) Eur J Biochem, 173, 171-8). Annexin V
is a member of the calcium dependent phospholipid binding
annexin/lipocortin protein family. It is composed of 320
amino acid residues folded into a planar cyclical arrangement
of four 70-amino acid repeats (Huber, et al. (1992) Behring
Inst Mitt, 107-25). Most cells and tissues express annexin V
(Kaetzel, et al. (1989) Biochem Biophys Res Commun, 160,
1233-7). Some known activities of annexin V include collagen binding (Pfaffie, et al. (1988) EMBO J, 7, 2335-42),
formation of voltage dependent calcium charmels (Rojas, et
al. (1990) J Biol Chem, 265, 21207-15) and inhibition of
phospholipase A2 (Pepinsky, et al. (1988) J Biol Chem, 263,
10799-811) and protein kinase C (Schlaepfer, et al. (1992)
Biochemistry, 31, 1886-91 ). The high affinity ofannexin V for
phospholipids has been exploited as a measure of apoptosis in
a variety of cell types. Early apoptosis is characterized by
exposure of phospholipids to the matrix side of the membrane
(Fadok, et al. (1992) J Immunol, 148, 2207-16). Fluorescentlabeled annexin V binding to the newly exposed phospholipids is used to identify and quantitate apoptotic cells (Koopman, et al. (1994) Blood, 84, 1415-20; and Vennes, et al.
(1995) J Immunol Methods, 184, 39-51).
These data show that both 14-3-3 and Annexin V are
cleared by Omi/HtrA2 and are physiological substrates of
Omi/HtrA2.
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SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS, 7
<210>
<211>
<212>
<213>
<220>
<223>
<220>
<221>
<222>
<223>
<220>
<221>
<222>
<223>

SEQ ID NO 1
LENGTH, 9
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, artificial protein sequence
FEATURE,
NAME/KEY, misc_feature
LOCATION, (5) .. (6)
OTHER INFORMATION, Xaa can be any naturally occurring amino acid
FEATURE,
NAME/KEY, misc_feature
LOCATION, (8) .. (9)
OTHER INFORMATION, Xaa can be any naturally occurring amino acid

<400> SEQUENCE, 1
Pro Arg Ala Ala Xaa Xaa Thr Xaa Xaa
1
5

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 2
LENGTH, 52
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Primer sequence

<400> SEQUENCE, 2
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-continued

tcgaattcgc tgggggagga gacagtactg tctcctcccc cagcgaattt tt

52

<210> SEQ ID NO 3
<211> LENGTH, 53
<212> TYPE, DNA
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, Primer sequence
<400> SEQUENCE, 3
taagcgaccc cctcctctgt catgacagag gagggggtcg cttaaaaatc tag

53

<210> SEQ ID NO 4
<211> LENGTH, 18
<212> TYPE, DNA
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, Primer sequence
<400> SEQUENCE, 4
gcggggcggg gtgcaaac

18

<210> SEQ ID NO 5
<211> LENGTH, 17
<212> TYPE, DNA
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, Primer Sequence
<400> SEQUENCE, 5
gacagccagc accgtgg

17

<210> SEQ ID NO 6
<211> LENGTH, 17
<212> TYPE, DNA
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, Primer Sequence
<400> SEQUENCE,
ttcgttgccg gtccaca

17

<210> SEQ ID NO 7
<211> LENGTH, 18
<212> TYPE, DNA
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, Primer sequence
<400> SEQUENCE, 7
accagcgcag cgatatcg

18
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What is claimed is:

(II)

1. A pharmaceutical composition for inhibiting cellular
apoptosis, the composition comprising at least one apoptosis
inhibiting compound that can modulate caspase-independent
apoptosis and a pharmaceutically acceptable carrier, wherein
the apoptosis inhibiting compound has the structure:

10
(I)

15

20

25

wherein Rl is selected from the group consisting of a nitro
group, a carboxy group, a hydroxide, an aliphatic group, an
aromatic group, an acyl group, an alkoxy group, an alkeylene
group, an alkenylene group, an alkynylene group, a hydroxycarbonylalkyl group, an anhydride, an amide, an amine, and a
heterocyclic aromatic group, an wherein R2 is a methoxy
group.
5. The pharmaceutical composition of claim 4, wherein the
apoptosis inhibiting compound is

~

wherein Rl is selected from the group consisting of a nitro
group, a carboxy group, a hydroxide, an aliphatic group, an
aromatic group, an acyl group, an alkoxy group, an alkeylene
group, an alkenylene group, an alkynylene group, a hydroxycarbonylalkyl group, an anhydride, an amide, an amine, and a
heterocyclic aromatic group.

s

~·

~N~N~

30

0
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2. The pharmaceutical composition of claim 1 further comprising a pharmaceutical acceptable excipient.
3. The pharmaceutical composition of claim 1, wherein the 40

apoptosis inhibiting compound is
Cl

~

s

~·

~N~N~
0

_a
45

50

6. A pharmaceutical composition for inhibiting cellular
apoptosis, the composition comprising at least one apoptosis
inhibiting compound that can modulate caspase-independent
apoptosis and a pharmaceutically acceptable carrier, wherein
the apoptosis inhibiting compound has the structure:
(III)

o1

O=W

55

60

4. A pharmaceutical composition, for inhibiting cellular
apoptosis, the composition comprising at least one apoptosis
inhibiting compound that can modulate caspase-independent
apoptosis and a pharmaceutically acceptable carrier, wherein
the apoptosis inhibiting compound has the structure:

65
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wherein Rl is selected from the group consisting of a nitro
group, a carboxy group, a hydroxide, an aliphatic group, an
aromatic group, an acyl group, an alkoxy group, an alkeylene
group, an alkenylene group, an alkynylene group, a hydroxycarbonylalkyl group, an anhydride, an amide, an amine, and a
heterocyclic aromatic group.
7. The pharmaceutical composition of claim 6, wherein the
apoptosis inhibiting compound is

9. The pharmaceutical composition of claim 8, wherein the

apoptosis inhibiting compound is

~

5

s

~·

~N~N~
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~N~N~
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10. The pharmaceutical composition of claim 1, wherein
the apoptosis inhibiting compound alters a functional activity
ofOmi/HtrA2.
25
11. The pharmaceutical composition of claim 1, wherein
0
the apoptosis inhibiting compound inhibits Omi/HtrA2 proteolytic activity.
0
12. The pharmaceutical composition of claim 1, wherein
the apoptosis inhibiting compound inhibits Omi/HtrA2 activ30
ity at least about 20% to about 90%.
13. The pharmaceutical composition of claim 3, wherein
the apoptosis inhibiting compound alters a functional activity
8. A pharmaceutical composition for inhibiting cellular
ofOmi/HtrA2.
apoptosis, the composition comprising at least one apoptosis
14. The pharmaceutical composition of claim 4, wherein
35
inhibiting compound that can modulate caspase-independent
the apoptosis inhibiting compound alters a functional activity
apoptosis and a pharmaceutically acceptable carrier, wherein
ofOmi/HtrA2.
the apoptosis inhibiting compound has the structure:
15. The pharmaceutical composition of claim 5, wherein
the apoptosis inhibiting compound alters a functional activity
40 ofOmi/HtrA2.
16. The pharmaceutical composition of claim 6, wherein
the apoptosis inhibiting compound alters a functional activity
(IV)
of0mi/HtrA2.
17. The pharmaceutical composition of claim 7, wherein
45 the apoptosis inhibiting compound alters a functional activity
ofOmi/HtrA2.
18. The pharmaceutical composition of claim 8, wherein
the apoptosis inhibiting compound alters a functional activity
o
ofOmi/HtrA2.
50
19. The pharmaceutical composition of claim 9, wherein
the apoptosis inhibiting compound alters a functional activity
ofOmi/HtrA2.
20. The pharmaceutical composition of claim 3, wherein
the apoptosis inhibiting compound inhibits Omi/HtrA2 pro55 teolytic activity.
21. The pharmaceutical composition of claim 4, wherein
the apoptosis inhibiting compound inhibits Omi/HtrA2 proteolytic activity.
22. The pharmaceutical composition of claim 5, wherein
60 the apoptosis inhibiting compound inhibits Omi/HtrA2 proteolytic activity.
wherein Rl is selected from the group consisting of a nitro
23. The pharmaceutical composition of claim 6, wherein
group, a carboxy group, a hydroxide, an aliphatic group, an
the apoptosis inhibiting compound inhibits Omi/HtrA2 proaromatic group, an acyl group, an alkoxy group, an alkeylene
teolytic activity.
group, an alkenylene group, an alkynylene group, a hydroxy- 65
24. The pharmaceutical composition of claim 7, wherein
the apoptosis inhibiting compound inhibits Omi/HtrA2 procarbonylalkyl group, an anhydride, an amide, an amine, and a
teolytic activity.
heterocyclic aromatic group.
0
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25. The pharmaceutical composition of claim 8, wherein

the apoptosis inhibiting compound inhibits Omi/HtrA2 proteolytic activity.
26. The pharmaceutical composition of claim 9, wherein
the apoptosis inhibiting compound inhibits Omi/HtrA2 proteolytic activity.
27. The pharmaceutical composition of claim 3, wherein
the apoptosis inhibiting compound inhibits Omi/HtrA2 activity at least about 20% to about 90%.
28. The pharmaceutical composition of claim 4, wherein
the apoptosis inhibiting compound inhibits Omi/HtrA2 activity at least about 20% to about 90%.
29. The pharmaceutical composition of claim 5, wherein
the apoptosis inhibiting compound inhibits Omi/HtrA2 activity at least about 20% to about 90%.
30. The pharmaceutical composition of claim 6, wherein
the apoptosis inhibiting compound inhibits Omi/HtrA2 activity at least about 20% to about 90%.
31. The pharmaceutical composition of claim 7, wherein
the apoptosis inhibiting compound inhibits Omi/HtrA2 activity at least about 20% to about 90%.
32. The pharmaceutical composition of claim 8, wherein
the apoptosis inhibiting compound inhibits Omi/HtrA2 activity at least about 20% to about 90%.
33. The pharmaceutical composition of claim 9, wherein
the apoptosis inhibiting compound inhibits Omi/HtrA2 activity at least about 20% to about 90%.
34. A pharmaceutical composition for inhibiting cellular
apoptosis, the composition comprising at least two apoptosis
inhibiting compounds that can modulate caspase-independent apoptosis and a pharmaceutically acceptable carrier,
wherein the apoptosis inhibiting compounds are
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